10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x    Quarterly Report Under Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2014

o    Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File Number: 1-8351

CHEMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	31-0791746
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)
255 E. Fifth Street, Suite 2600, Cincinnati, Ohio	45202
(Address of principal executive offices)	(Zip code)

(513) 762-6690

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer x Accelerated filer o Non-accelerated filer o Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Amount	Date
Capital Stock $1 Par Value	17,010,464 Shares	September 30, 2014

-1-

CHEMED CORPORATION AND

SUBSIDIARY COMPANIES

Index

	Page No.
PART I.    FINANCIAL INFORMATION:
Item 1.  Financial Statements
Unaudited Consolidated Balance Sheet - September 30, 2014 and December 31, 2013	3
Unaudited Consolidated Statement of Income - Three and nine months ended September 30, 2014 and 2013	4
Unaudited Consolidated Statement of Cash Flows - Nine months ended September 30, 2014 and 2013	5
Notes to Unaudited Consolidated Financial Statements	6
Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.  Quantitative and Qualitative Disclosures about Market Risk	32
Item 4.  Controls and Procedures	32
PART II.   OTHER INFORMATION
Item 1.    Legal Proceedings	32
Item 1A. Risk Factors	32
Item 2.    Unregistered Sales of Equity Securities and Use of  Proceeds	33
Item 3.    Defaults Upon Senior Securities	33
Item 4.    Mine Safety Disclosures	33
Item 5.    Other Information	33
Item 6.    Exhibits	34
EX – 31.1
EX – 31.2
EX – 31.3
EX – 32.1
EX – 32.2
EX – 32.3
EX – 101.INS
EX – 101.SCH
EX – 101.CAL
EX – 101.DEF
EX – 101.LAB
EX – 101.PRE

-2-

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
UNAUDITED CONSOLIDATED BALANCE SHEET
(in thousands, except share and per share data)
	September 30, 2014			December 31, 2013
ASSETS
Current assets
Cash and cash equivalents	$	18,562		$	84,418
Accounts receivable less allowances of $13,887 (2013 - $12,590)		132,340			91,770
Inventories		6,385			6,703
Current deferred income taxes		14,543			20,257
Prepaid income taxes		3,488			3,690
Prepaid expenses		13,420			17,818
Total current assets		188,738			224,656
Investments of deferred compensation plans		47,780			42,465
Properties and equipment, at cost, less accumulated depreciation of $187,983 (2013 - $180,550)		101,845			92,955
Identifiable intangible assets less accumulated amortization of $32,644 (2013 - $32,055)		56,158			56,556
Goodwill		466,844			466,871
Other assets		8,143			10,198
Total Assets	$	869,508		$	893,701
LIABILITIES
Current liabilities
Accounts payable	$	57,067		$	41,758
Current portion of long-term debt		20,425			183,564
Income taxes		4,608			111
Accrued insurance		39,927			41,859
Accrued compensation		50,412			48,323
Accrued legal		685			23,210
Other current liabilities		24,131			25,161
Total current liabilities		197,255			363,986
Deferred income taxes		27,853			27,301
Long-term debt		153,125			-
Deferred compensation liabilities		47,736			42,348
Other liabilities		11,108			11,176
Total Liabilities		437,077			444,811
Commitments and contingencies
STOCKHOLDERS' EQUITY
Capital stock - authorized 80,000,000 shares $1 par; issued 33,199,078 shares (2013 - 32,245,226 shares)		33,199			32,245
Paid-in capital		528,973			481,011
Retained earnings		745,077			686,114
Treasury stock - 16,287,526 shares (2013 - 14,660,427)		(877,067	)		(752,634	)
Deferred compensation payable in Company stock		2,249			2,154
Total Stockholders' Equity		432,431			448,890
Total Liabilities and Stockholders' Equity	$	869,508		$	893,701

See accompanying notes to unaudited consolidated financial statements.

-3-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
UNAUDITED CONSOLIDATED STATEMENT OF INCOME
(in thousands, except per share data)
	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Service revenues and sales	$	358,389		$	340,886		$	1,076,871		$	1,064,725
Cost of services provided and goods sold (excluding depreciation)		256,445			243,184			771,271			762,850
Selling, general and administrative expenses		53,566			48,870			162,886			157,537
Depreciation		7,450			6,971			21,871			20,665
Amortization		717			1,190			2,461			3,498
Other operating expenses		-			11,461			-			26,221
Total costs and expenses		318,178			311,676			958,489			970,771
Income from operations		40,211			29,210			118,382			93,954
Interest expense		(980	)		(3,500	)		(7,224	)		(11,291	)
Other income - net		705			(90	)		2,277			3,312
Income before income taxes		39,936			25,620			113,435			85,975
Income taxes		(15,351	)		(8,188	)		(43,913	)		(31,657	)
Net income	$	24,585		$	17,432		$	69,522		$	54,318
Earnings Per Share
Net income	$	1.44		$	0.96		$	4.03		$	2.95
Average number of shares outstanding		17,039			18,184			17,263			18,436
Diluted Earnings Per Share
Net income	$	1.39		$	0.94		$	3.87		$	2.89
Average number of shares outstanding		17,627			18,522			17,968			18,824
Cash Dividends Per Share	$	0.22		$	0.20		$	0.62		$	0.56

See accompanying notes to unaudited consolidated financial statements.

-4-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS
(in thousands)
	Nine Months Ended September 30,
	2014			2013
Cash Flows from Operating Activities
Net income	$	69,522		$	54,318
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization		24,332			24,163
Deferred income taxes		5,630			(11,681	)
Provision for uncollectible accounts receivable		9,573			8,211
Amortization of discount on convertible notes		3,392			6,450
Stock option expense		3,430			4,732
Amortization of debt issuance costs		697			1,421
Noncash long-term incentive compensation		1,988			1,161
Changes in operating assets and liabilities, excluding
amounts acquired in business combinations:
Decrease/(increase) in accounts receivable		(50,027	)		5,293
Decrease in inventories		318			329
Decrease/(increase) in prepaid expenses		4,398			(6,183	)
Increase/(decrease) in accounts payable and other current liabilities		(29,680	)		48,967
Increase in income taxes		8,186			1,923
Increase in other assets		(3,138	)		(5,002	)
Increase in other liabilities		5,370			3,978
Excess tax benefit on share-based compensation		(3,737	)		(2,507	)
Other sources		755			285
Net cash provided by operating activities		51,009			135,858
Cash Flows from Investing Activities
Capital expenditures		(31,745	)		(18,887	)
Business combinations, net of cash acquired		(250	)		(2,210	)
Other sources		189			139
Net cash used by investing activities		(31,806	)		(20,958	)
Cash Flows from Financing Activities
Proceeds from revolving line of credit		308,600			-
Payments on revolving line of credit		(233,800	)		-
Payments on other long-term debt		(188,206	)		-
Proceeds from other long-term debt		100,000			-
Purchases of treasury stock		(99,103	)		(89,611	)
Dividends paid		(10,558	)		(10,459	)
Capital stock surrendered to pay taxes on stock-based compensation		(6,121	)		(4,280	)
Retirement of warrants		(2,645	)		-
Proceeds from exercise of stock options		22,123			13,125
Excess tax benefit on share-based compensation		3,737			2,507
Increase/(decrease) in cash overdrafts payable		22,233			(10,928	)
Debt issuance costs		(939	)		(1,108	)
Other uses		(380	)		(473	)
Net cash used by financing activities		(85,059	)		(101,227	)
Increase/(Decrease) in Cash and Cash Equivalents		(65,856	)		13,673
Cash and cash equivalents at beginning of year		84,418			69,531
Cash and cash equivalents at end of period	$	18,562		$	83,204

See accompanying notes to unaudited consolidated financial statements.

-5-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

Notes to Unaudited Consolidated Financial Statements

1.   Basis of Presentation

As used herein, the terms "We," "Company" and "Chemed" refer to Chemed Corporation or Chemed Corporation and its consolidated subsidiaries.

We have prepared the accompanying unaudited consolidated financial statements of Chemed in accordance with Rule 10-01 of SEC Regulation S-X.  Consequently, we have omitted certain disclosures required under generally accepted accounting principles in the United States (“GAAP”) for complete financial statements. The December 31, 2013 balance sheet data were derived from audited financial statements but do not include all disclosures required by GAAP.  However, in our opinion, the financial statements presented herein contain all adjustments, consisting only of normal recurring adjustments, necessary to state fairly our financial position, results of operations and cash flows.  These financial statements are prepared on the same basis as and should be read in conjunction with the audited Consolidated Financial Statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2013.

2.   Revenue Recognition

Both the VITAS segment and the Roto-Rooter segment recognize service revenues and sales when the earnings process has been completed.  Generally, this occurs when services are provided or products are delivered.  VITAS recognizes revenue at the estimated realizable amount due from third-party payers.  Medicare payments are subject to certain limitations, as described below.

We actively monitor each of our hospice programs, by provider number, as to their specific admission, discharge rate and median length of stay data in an attempt to determine whether they are likely to exceed the annual per-beneficiary Medicare cap (“Medicare cap”).  Should we determine that revenues for a program are likely to exceed the Medicare cap based on projected trends, we attempt to institute corrective action to influence the patient mix or to increase patient admissions.  However, should we project our corrective action will not prevent that program from exceeding its Medicare cap, we estimate the amount of revenue recognized during the period that will require repayment to the Federal government under the Medicare cap and record the amount as a reduction to patient revenue.

During the third quarter of 2014, we recorded $2.5 million Medicare cap liability for two programs’ projected 2014 measurement period liability.

During the nine months ended September 30, 2014 we recorded a net Medicare cap liability of $1.8 million for two programs’ projected 2014 measurement period liability offset by the reversal of Medicare cap liability for amounts recorded in the fourth quarter of 2013 for projected 2014 measurement period liability. Also during the nine months ended September 30, 2014, we received notice from a third party intermediary for amounts accrued related to the 2013 measurement period. As a result we repaid $3.4 million.

Shown below is the Medicare cap liability activity for the fiscal periods ended (in thousands):

	September 30,
	2014			2013
Beginning balance January 1,	$	8,260		$	1,261
2014 measurement period		1,796			-
2013 measurement period		-			3,161
Payments		(3,439	)		-
Ending balance September 30,	$	6,617		$	4,422

Vitas provides charity care, in certain circumstances, to patients without charge when management of the hospice program determines, at the time services are performed, that the patient does not have the financial wherewithal to make payment.  There is no revenue or associated accounts receivable in the accompanying consolidated financial statements related to charity care.  The cost of charity care is calculated by taking the ratio of charity care days to total days of care and multiplying by total cost of care.  The cost of charity care is as follows (in thousands):

-6-

Three months ended September 30,				Nine months ended September 30,
2014		2013		2014		2013
$	1,827	$	1,909	$	5,518	$	5,793

3.   Segments

Service revenues and sales and after-tax earnings by business segment are as follows (in thousands):

	Three months ended September 30,						Nine months ended September 30,
	2014			2013			2014			2013
Service Revenues and Sales
VITAS	$	265,384		$	254,001		$	789,822		$	788,896
Roto-Rooter		93,005			86,885			287,049			275,829
Total	$	358,389		$	340,886		$	1,076,871		$	1,064,725
After-tax Earnings
VITAS	$	21,593		$	14,608		$	60,645		$	55,237
Roto-Rooter		9,848			8,181			30,599			19,218
Total		31,441			22,789			91,244			74,455
Corporate		(6,856	)		(5,357	)		(21,722	)		(20,137	)
Net income	$	24,585		$	17,432		$	69,522		$	54,318

We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as “Corporate”.

4.  Earnings per Share

Earnings per share (“EPS”) are computed using the weighted average number of shares of capital stock outstanding.  Earnings and diluted earnings per share are computed as follows (in thousands, except per share data):

		Net Income
For the Three Months Ended September 30,		Income		Shares		Earnings per Share
2014
	Earnings	$	24,585		17,039	$	1.44
	Dilutive stock options		-		416
	Nonvested stock awards		-		151
	Impact of warrants outstanding		-		21
	Diluted earnings	$	24,585		17,627	$	1.39
2013
	Earnings	$	17,432		18,184	$	0.96
	Dilutive stock options		-		235
	Nonvested stock awards		-		103
	Diluted earnings	$	17,432		18,522	$	0.94

-7-

		Net Income
For the Nine Months Ended September 30,		Income		Shares		Earnings per Share
2014
	Earnings	$	69,522		17,263	$	4.03
	Dilutive stock options		-		402
	Nonvested stock awards		-		147
	Conversion of Notes and impact of warrants outstanding		-		156
	Diluted earnings	$	69,522		17,968	$	3.87
2013
	Earnings	$	54,318		18,436	$	2.95
	Dilutive stock options		-		287
	Nonvested stock awards		-		101
	Diluted earnings	$	54,318		18,824	$	2.89

For the three and nine-month periods ended September 30, 2014, no stock options were excluded from the computation of diluted earnings per share because they would have been anti-dilutive. For the three and nine-month periods ended September 30, 2013, 434,000 and 31,000 stock options, respectively, were excluded from the computation of diluted earnings per share.

Diluted earnings per share was impacted by the issuance of 249,000 shares of capital stock under the conversion feature of our 1.875% Senior Convertible Notes (the “Notes”) on May 15, 2014.  The dilutive impact of this conversion feature for the first nine months of 2014 was 135,000 shares.

At the time we issued the Notes, as discussed in Note 5 below, we also sold warrants for the right to purchase approximately 2,477,000 Chemed shares in the future.  During the quarter ended June 30, 2014, we settled these warrants with one counterparty representing half of the total warrants issued for $2.6 million.  The amount paid was recorded as an adjustment to paid-in capital.   The remaining half of the sold warrants remain outstanding and mature ratably from August 15 through December 8, 2014.  The dilutive impact of the warrants was 21,000 shares for the three and nine months periods ended September 30, 2014.

5.   Long-Term Debt

On May 15, 2014, we retired our Senior Convertible Notes (the “Notes”) outstanding.  We paid the $187.0 million of principal outstanding using a combination of cash on-hand and our existing revolving credit facility.  In addition, we issued 249,000 Chemed shares in conjunction with the conversion feature of the Notes.  At the time we issued the Notes, we also entered into a purchased call transaction to offset any potential economic dilution resulting from the conversion feature in the Notes.  As a result, we received 266,000 Chemed shares from the exercise of the purchased call transaction.  The issuance of shares under the conversion feature of the Notes, as well as the receipt of shares from the purchased call transaction were recorded as adjustments to paid-in capital during the quarter ended June 30, 2014.

On June 30, 2014, we replaced our existing credit agreement with the Third Amended and Restated Credit Agreement (“2014 Credit Agreement”).  Terms of the 2014 Credit Agreement consist of a five-year, $350 million revolving credit facility and a $100 million term loan.  The 2014 Credit Agreement has a floating interest rate that is currently LIBOR plus 113 basis points.

The debt outstanding consists of the following:

Revolver	$	74,800,000
Term loan		98,750,000
Total		173,550,000
Current portion of term and revolving loan		(20,425,000	)
Long-term debt	$	153,125,000

-8-

Scheduled principal payments of the term loan are as follows:

2014	$	1,250,000
2015		6,250,000
2016		7,500,000
2017		8,750,000
2018		10,000,000
2019		65,000,000
	$	98,750,000

Debt issuance costs associated with the existing credit agreement were not written-off as the lenders and their relative percentage participation in the facility did not change. With respect to the 2014 Credit Agreement, deferred financing costs were $0.9 million.  The 2014 Credit Agreement contains the following quarterly financial covenants:

Description	Requirement
Leverage Ratio (Consolidated Indebtedness/Consolidated  Adj. EBITDA)	< 3.50 to 1.00
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges)	> 1.50 to 1.00
Annual Operating Lease Commitment	< $50.0 million

We are in compliance with all debt covenants as of September 30, 2014. We have issued $36.9 million in standby letters of credit as of September 30, 2014 for insurance purposes.  Issued letters of credit reduce our available credit under the 2014 Credit Agreement.  As of September 30, 2014, we have approximately $238.3 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility.

6.   Other Income – Net

Other income -- net comprises the following (in thousands):

	Three months ended September 30,						Nine months ended September 30,
	2014			2013			2014			2013
Market value gains/(losses) on assets held in
deferred compensation trust	$	896		$	(189	)	$	2,708		$	2,346
Loss on disposal of property and equipment		(167	)		(101	)		(493	)		(180	)
Interest income - net		(13	)		192			(5	)		1,165
Other - net		(11	)		8			67			(19	)
Total other income - net	$	705		$	(90	)	$	2,277		$	3,312

 7.   Stock-Based Compensation Plans

On February 21, 2014, the Compensation/Incentive Committee of the Board of Directors (“CIC”) granted 10,340 Performance Stock Units (“PSUs”) contingent upon the achievement of certain total shareholders return (“TSR”) targets as compared to the TSR of a group of peer companies for the three-year period ending December 31, 2016, the date at which such awards may vest.  The cumulative compensation cost of the TSR-based PSU award to be recorded over the three year service period is $1.2 million.

On February 21, 2014, the CIC also granted 14,061 PSUs contingent upon the achievement of certain earnings per share (“EPS”) targets for the three-year period ending December 31, 2016.  At the end of each reporting period, the Company estimates the number of shares that it believes will ultimately be earned and records that expense over the service period of the award.  We currently estimate the cumulative compensation cost of the EPS-based PSUs to be recorded over the three year service period is $1.2 million.

-9-

8.   Independent Contractor Operations

The Roto-Rooter segment sublicenses with 68 independent contractors to operate certain plumbing repair and drain cleaning businesses in lesser-populated areas of the United States and Canada.  We had notes receivable from our independent contractors as of September 30, 2014 totaling $1.4 million (December 31, 2013 - $1.5 million).  In most cases these loans are fully or partially secured by equipment owned by the contractor.  The interest rates on the loans range from 0% to 8% per annum and the remaining terms of the loans range from 2 months to 5 years at September 30, 2014.  We recorded the following from our independent contractors (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2014		2013		2014		2013
Revenues	$	8,751	$	8,054	$	26,964	$	24,418
Pretax profits		4,946		4,243		15,341		13,015

9.   Retirement Plans

All of the Company’s plans that provide retirement and similar benefits are defined contribution plans.  These expenses include the impact of market gains and losses on assets held in deferred compensation plans.  Expenses for the Company’s pension and profit-sharing plans, excess benefit plans and other similar plans are as follows (in thousands):

Three months ended September 30,				Nine months ended September 30,
2014		2013		2014		2013
$	3,635	$	2,098	$	10,856	$	9,796

10.  Legal and Regulatory Matters

The VITAS segment of the Company’s business operates in a heavily-regulated industry.  As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including qui tam actions.  The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware.  It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or estimable.

Regulatory Matters and Litigation

On January 12, 2012, a putative class action lawsuit was filed in the U.S. District Court for the Southern District of Ohio against the Company, David Williams, and Timothy O’Toole, In re Chemed Corp. Securities Litigation, Civil Action No. 1:12-cv-28 (S.D. Ohio).  As the Company has previously disclosed, on February 6, 2014, the Plaintiffs, on behalf of a putative class of purchasers of Chemed Capital Stock between February 15, 2010 and May 2, 2013, inclusive, executed a stipulation of settlement with Defendants.  That settlement received final court approval on July 15, 2014, resulting in the dismissal of the case.  No appeal of that judgment has since been filed.  Defendants agreed to enter into this settlement in order to eliminate the burden, expense and distraction of further litigation.

In June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Western District of Texas,  United States, et al. ex rel. Urick v. VITAS HME Solutions, Inc. et al., 5:08-cv-0663 (“Urick”).  The U.S. Attorney filed a notice in May 2012 stating that it had decided not to intervene in the case at that time but indicating that it continues to investigate the allegations.  In June 2012, the complaint was unsealed.  The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on allegations of a conspiracy to submit to Medicare and Medicaid false claims involving hospice services for ineligible patients, unnecessary medical supplies, failing to satisfy certain prerequisites for payment, and altering patient records, including backdating patient revocations.  The suit was brought by Barbara Urick, a registered nurse in VITAS’s San Antonio program, against VITAS, certain of its affiliates, and several former VITAS employees, including physicians Justo Cisneros and Antonio Cavasos and nurses Sally Schwenk, Diane Anest, and Edith Reed.  In September 2012 and July 2013, the plaintiff dismissed all claims against the individual defendants.  The complaint was served on the VITAS entities on April 12, 2013.

-10-

Also in June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Northern District of Illinois, United States, et al. ex rel. Spottiswood v. Chemed Corp., 1:07-cv-4566 (“Spottiswood”).  In April 2012, the complaint was unsealed.  The U.S. Attorney and Attorney General for the State of Illinois filed notices in April and May 2012, respectively, stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations.  Plaintiff filed an amended complaint in November 2012.  The complaint asserts violations of the federal False Claims Act and the Illinois Whistleblower Reward and Protection Act based on allegations that VITAS fraudulently billed Medicare and Medicaid for providing unwarranted continuous care services.  The suit was brought by Laura Spottiswood, a former part-time pool registered nurse at VITAS, against Chemed, VITAS, and a VITAS affiliate.  The complaint was served on the defendants on April 12, 2013.  On May 29 and June 4, 2013, respectively, the Court granted the government’s motion to partially intervene in Spottiswood and in Urick on the allegations that VITAS submitted or caused to be submitted false or fraudulent claims for continuous care and routine home care on behalf of certain ineligible Medicare beneficiaries.  The Court also transferred them to the U.S. District Court for the Western District of Missouri under docket Nos. 4:13-cv-505 and 4:13-cv-563, respectively.

On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, United States v. VITAS Hospice Services, LLC, et al., No. 4:13-cv-00449-BCW (the “2013 Action”).  Prior to that date, the Company received various subpoenas from the U.S. Department of Justice and OIG that have been previously disclosed.  The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course.  This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest.  On August 1, 2013, the government filed its First Amended Complaint in the 2013 Action.  The First Amended Complaint changed and supplemented some of the allegations, but did not otherwise expand the causes of action or the nature of the relief sought against VITAS.  The defendants filed a motion to dismiss on September 24, 2013.  The Court denied the motion, except to the extent that claims were filed before July 24, 2002, on September 30, 2014. 

On May 6, 2013, the U.S. District Court for the Western District of Missouri, at the request of the government, unsealed a qui tam complaint against VITAS and VITAS Healthcare Corporation of California, United States ex rel. Charles Gonzales v. VITAS Healthcare Corporation, et al., CV 12-0761-R (“Gonzales”).  The case was transferred from the Central District of California to the Western District of Missouri under docket No. 4:13-cv-344.  The government partially intervened in Gonzales.  The Gonzales complaint alleges that VITAS’ Los Angeles program falsely certified and recertified patients as eligible for the Medicare Hospice Benefit.  It alleges violations of the False Claims Act and seeks treble damages, civil penalties, recovery of costs, attorneys’ fees and expenses, and pre- and post-judgment interest.  

On September 25, 2013, the Court granted a joint motion by the government, the relators, and VITAS to consolidate the Spottiswood,  Urick, and  Gonzales complaints with the 2013 Action.  As a result, the First Amended Complaint will govern the consolidated federal claims brought by the United States and the relators for all purposes.  The relators and VITAS have stipulated that certain non-intervened claims will not be pursued by the relators.  The Spottiswood relator filed an action under the Illinois False Claims Act, The State of Illinois ex rel. Laura Spottiswood v. Chemed Corporation, et al., No. 14 L 2786 in the Circuit Court of Cook County, Illinois on March 6, 2014.  The Court granted the parties’ joint motion to place this case on its stay calendar, pending resolution of the 2013 Action.

VITAS has also received document subpoenas in related state matters.  In February 2010, VITAS received a civil investigative demand (“CID”) from the Texas Attorney General seeking documents from January 1, 2002 through the date of the CID, and interrogatory responses in connection with an investigation of possible fraudulent submission of Medicaid claims for non-qualifying patients and fraudulent shifting of costs from VITAS to the State of Texas and the United States.  The CID requested similar information sought by prior Department of Justice subpoenas, including policy and procedure manuals and information concerning Medicare and Medicaid billing, patient statistics and sales and marketing practices, together with information concerning record-keeping and retention practices, and medical records concerning 117 patients.  In September 2010, VITAS received a third CID from the Texas Attorney General seeking additional documents concerning business plans and results, revocation forms for certain patients, and electronic documents of 10 current and former employees.  In July 2012, VITAS received an investigative subpoena from the Florida Attorney General seeking documents previously produced in the course of prior government investigations as well as, for the period January 1, 2007 through the date of production, billing records and procedures; information concerning business results, plans, and strategies; documents concerning patient eligibility for hospice care; and certain information concerning employees and their compensation.

-11-

The net costs incurred related to U.S. v. Vitas and related regulatory matters were $450,000 and a $591,000 credit for the three months ended September 30, 2014 and 2013, respectively.  For the nine months ended September 30, 2014 and 2013, the net costs were $1.6 million and $1.4 million respectively.

In November 2013, two shareholder derivative lawsuits were filed against the Company’s current and former directors, as well as certain of its officers, both of which are covered by the Company’s commercial insurance.  On November 6, 2013, KBC Asset Management NV filed suit in the United States District Court for the District of Delaware, KBC Asset Management NV, derivatively on behalf of Chemed Corp. v. McNamara, et al., No. 13 Civ. 1854 (LPS) (D. Del.).  It sued Kevin McNamara, Joel Gemunder, Patrick Grace, Thomas Hutton, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, Arthur Tucker, Jr., George Walsh III, Frank Wood, Timothy O’Toole, David Williams and Ernest Mrozek, together with the Company as nominal defendant.  Plaintiff alleges that since at least 2004, Chemed, through VITAS, has submitted or caused the submission of false claims to Medicare.  The suit alleges a claim for breach of fiduciary duty against the individual defendants, and seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.

On November 14, 2013, Mildred A. North filed suit in the United States District Court for the Southern District of Ohio, North, derivatively on behalf of Chemed Corp. v. Kevin McNamara, el al., No. 13 Civ. 833 (MDB) (S.D. Ohio).  She sued Kevin McNamara, David Williams, Timothy O’Toole, Joel Gemunder, Patrick Grace, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, George Walsh III, Frank Wood and Thomas Hutton, together with the Company as nominal defendant.  Plaintiff alleges that, between February 2010 and the present, the individual defendants breached their fiduciary duties as officers and directors of Chemed by, among other things, (a) allegedly causing VITAS to submit improper and ineligible claims to Medicare and Medicaid; and (b) allegedly misrepresenting the state of Chemed’s internal controls.  The suit alleges claims for breach of fiduciary duty, abuse of control and gross mismanagement against the individual defendants.  The complaint also alleges unjust enrichment and insider trading against Messrs. McNamara, Williams and O’Toole.  Plaintiff seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.

On January 29, 2014 defendants in North filed a motion to transfer that case to Delaware under 28 U.S.C § 1404(a). On February 12, 2014, defendants in KBC filed a motion to dismiss that case pursuant to Federal Rules of Civil Procedure 23.1 and 12(b)(6).  On September 19, 2014, the Ohio court granted defendants’ motion to transfer North to Delaware.  Following that decision and in light of that transfer, on September 29, 2014, the Delaware court denied without prejudice defendants’ motion to dismiss KBC, and referred both cases to Magistrate Judge Burke.  Defendants intend to renew their motion to dismiss the claims and allegations in KBC once it has been determined how these two cases are to proceed.  On October 15, 2014, the plaintiff in KBC filed a motion seeking to consolidate KBC and North, to have plaintiff KBC appointed the sole lead plaintiff and its counsel, Motley Rice, sole lead counsel, and to designate KBC the sole operative complaint.  Plaintiff North has indicated that she does not oppose consolidation of the two cases, but otherwise opposes KBC’s motion with regard to the appointment of lead plaintiff and lead counsel and designation of the operative complaint.  On October 20, 2014, the Court stayed Defendants’ obligation to answer, move, or otherwise respond to the complaints in KBC and North pending further order of the Court.

The Company intends to defend vigorously against the allegations in each of the above lawsuits.  Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, diversion of management time, and related publicity.  Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.

-12-

11.   Concentration of Risk

VITAS has pharmacy services agreements ("Agreements") with Omnicare, Inc. and its subsidiaries (“OCR”) whereby OCR provides specified pharmacy services for VITAS and its hospice patients in geographical areas served by both VITAS and OCR.  The Agreements renew automatically for three-year terms.  Either party may cancel the Agreements at the end of any term by giving 30 days prior written notice.  VITAS made purchases from OCR of $8.8 million and $9.7 million for the three months ended September 30, 2014 and 2013, respectively.  VITAS made purchases from OCR of $26.5 million and $29.3 million for the nine months ended September 30, 2014 and 2013, respectively. For the three and nine month periods ending September 30, 2014 and 2013, respectively, purchases from this vendor represent approximately 90% of all pharmacy services used by VITAS.

12.   Cash Overdrafts and Cash Equivalents

Included in accounts payable at September 30, 2014 is cash overdrafts payable of $23.0 million (December 31, 2013 - $806,000).

From time to time throughout the year, we invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds.  We had $68,000 in cash equivalents as of September 30, 2014.  There was $23.1 million in cash equivalents as of December 31, 2013.  The weighted average rate of return for our cash equivalents was 0.09% at September 30, 2014 and 0.08% at December 31, 2013.

13.   Financial Instruments

FASB’s authoritative guidance on fair value measurements defines a hierarchy which prioritizes the inputs in fair value measurements.  Level 1 measurements are measurements using quoted prices in active markets for identical assets or liabilities.  Level 2 measurements use significant other observable inputs.  Level 3 measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions.  In recording the fair value of assets and liabilities, companies must use the most reliable measurement available.

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of September 30, 2014 (in thousands):

			Fair Value Measure
	Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Mutual fund investments of deferred compensation plans held in trust	$	47,780	$	47,780	$	-	$	-
Long-term debt		173,550		-		173,550		-

All outstanding long-term debt is at a floating interest rate tied to LIBOR. Therefore, the carrying amount is a reasonable estimation of fair value.

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of December 31, 2013 (in thousands):

			Fair Value Measure
	Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Mutual fund investments of deferred compensation plans held in trust	$	42,465	$	42,465	$	-	$	-
Long-term debt		183,564		193,032		-		-

For cash and cash equivalents, accounts receivable and accounts payable, the carrying amount is a reasonable estimate of fair value because of the liquidity and short-term nature of these instruments.

-13-

14.   Capital Stock Repurchase Plan Transactions

We repurchased the following capital stock for the three and nine-months ended September 30, 2014 and 2013:

	Three months ended September 30,				Nine months ended September 30,
	2014		2013		2014		2013
Shares repurchased		400,000		1,032,754		1,082,934		1,313,455
Weighted average price per share	$	101.53	$	68.91	$	91.51	$	68.23

In February 2014, the Board of Directors authorized an additional $100 million for stock repurchase under Chemed’s existing share repurchase program. We currently have $22.7 million of authorization remaining under this share repurchase plan.

15.   Recent Accounting Statements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update “ASU No. 2014-09 – Revenue from Contracts with Customers” which provides additional guidance to clarify the principles for recognizing revenue.  The standard will also be used to develop a common revenue standard for removing inconsistencies and weaknesses, improve comparability, provide more useful information to users through improved disclosure requirements, and simplify the preparation of financial statements.  The guidance is effective for fiscal years beginning after December 15, 2016.  We are currently evaluating the impact of this ASU on our existing revenue recognition policies and disclosures.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “ASU No. 2014-15 - Presentation of Financial Statements-Going Concern”.   ASU 2014-15 is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. This guidance is effective for us for the annual period ending December 31, 2016 and interim periods thereafter. We do not expect the adoption of this standard to have a material impact on our consolidated financial position, results of operations and cash flows.

-14-

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc.  VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible.  Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families.  Roto-Rooter’s services are focused on providing plumbing and drain cleaning services to both residential and commercial customers.  Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The following is a summary of the key operating results (in thousands except per share amounts):

	Three months ended September 30,						Nine months ended September 30,
	2014			2013			2014			2013
Service revenues and sales	$	358,389		$	340,886		$	1,076,871		$	1,064,725
Net income	$	24,585		$	17,432		$	69,522		$	54,318
Diluted EPS	$	1.39		$	0.94		$	3.87		$	2.89
Adjusted net income	$	26,058		$	25,098		$	76,351		$	78,470
Adjusted diluted EPS	$	1.48		$	1.36		$	4.28		$	4.17
Adjusted EBITDA	$	50,946		$	49,739		$	150,831		$	153,978
Adjusted EBITDA as a % of revenue		14.2	%		14.6	%		14.0	%		14.5	%

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”) and Adjusted EBITDA are not measures derived in accordance with GAAP.  We provide non-GAAP measures to help readers evaluate our operating results, compare our operating performance with that of similar companies that have different capital structures and help evaluate our ability to meet future debt service, capital expenditure and working capital requirements.  Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP.  A reconciliation of our non-GAAP measures are presented on pages 28-30.

For the three months ended September 30, 2014, the increase in consolidated service revenues and sales was driven by a 7.0% increase at Roto-Rooter and a 4.5% increase at VITAS.  The increase in service revenues at Roto-Rooter was driven by an increase in a combination of price and service mix shift offset by a decrease in job count. The remaining difference relates to increases in contractor revenue and increases in our water restoration business line.  Water restoration is the remediation of water and humidity damage after a flood.  The increase in service revenues at VITAS was a result of Medicare reimbursement rates increasing 1.4%, a 2.8% increase in average daily census and mix shift.  Consolidated net income increased 41.0% mainly as a result of lawsuit settlements in 2013 at Vitas and Roto-Rooter that did not repeat in 2014.   Diluted EPS increased 47.9% as a result of the increase in net income as well as a lower number of shares outstanding.  Adjusted EBITDA as a percent of revenue decreased 0.4%.   See page 31 for additional VITAS operating metrics.

For the nine months ended September 30, 2014, the increase in consolidated service revenues and sales was driven by a 4.1% increase at Roto-Rooter and a 0.1% increase at VITAS.  The increase in service revenues at Roto-Rooter was driven by an increase in a combination of price, and service mix shift offset by a decrease in job count. The remaining difference relates to increases in contractor revenue and increases in our water restoration business line.  Consolidated net income increased 28.0% mainly as a result of lawsuit settlements in 2013 at VITAS and Roto-Rooter that did not repeat in 2014.  Diluted EPS increased 33.9% as a result of the increase in net income as well as a lower number of shares outstanding.  Adjusted EBITDA as a percent of revenue decreased 0.5%. See page 31 for additional VITAS operating metrics.

On April 1, 2013, Medicare reduced hospice reimbursement rates 2.0%.  Effective October 1, 2013, Medicare increased the average hospice rate approximately 1.4% This effectively reduced Medicare hospice reimbursement 0.6% through the first quarter of 2014.  VITAS expects its full-year 2014 revenue growth, prior to Medicare cap, to be in the range of 1.0% to 2.0%.  Admissions in 2014 are estimated to increase 2.0%.  Adjusted EBITDA margin, prior to Medicare cap, is estimated to be 14.5% to 15.0%.  Medicare cap is estimated to be $3.6 million in 2014. Roto-Rooter expects full-year 2014 revenue growth of 4.0% to 5.0%.  The revenue estimate is a result of increased job pricing of approximately 2.0%. Adjusted EBITDA margin for 2014 is estimated in the range of 19.0% to 19.5%.  We anticipate that our operating income and cash flows will be sufficient to operate our businesses and meet any commitments for the foreseeable future.

-15-

Financial Condition

Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2013 to September 30, 2014 include the following:

● A $65.9 million decrease in cash due to purchases of treasury stock and capital expenditures, partially offset by cash generated by operations.

● A $40.6 million increase in accounts receivable related to the timing of payments.

● A $15.3 million increase in accounts payable due to timing of payments.

● A $10.0 million decrease in total long-term debt as a result of net payments of outstanding debt using cash on-hand.

● A $22.5 million decrease in accrued legal due to the payment of litigation settlements.

Net cash provided by operating activities decreased $84.8 million primarily as a result of the increase in accounts receivable and a decline in accrued legal expenses.  Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

We have issued $36.9 million in standby letters of credit as of September 30, 2014, for insurance purposes.  Issued letters of credit reduce our available credit under the revolving credit agreement.  As of September 30, 2014, we have approximately $238.3 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

Commitments and Contingencies

Collectively, the terms of our credit agreements require us to meet various financial covenants, to be tested quarterly.  We are in compliance with all financial and other debt covenants as of September 30, 2014 and anticipate remaining in compliance throughout 2014.

The VITAS segment of the Company’s business operates in a heavily-regulated industry.  As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including qui tam actions.  The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware.  It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or estimable.

On January 12, 2012, a putative class action lawsuit was filed in the U.S. District Court for the Southern District of Ohio against the Company, David Williams, and Timothy O’Toole, In re Chemed Corp. Securities Litigation, Civil Action No. 1:12-cv-28 (S.D. Ohio).  As the Company has previously disclosed, on February 6, 2014, the Plaintiffs, on behalf of a putative class of purchasers of Chemed Capital Stock between February 15, 2010 and May 2, 2013, inclusive, executed a stipulation of settlement with Defendants.  That settlement received final court approval on July 15, 2014, resulting in the dismissal of the case.  No appeal of that judgment has since been filed.  Defendants agreed to enter into this settlement in order to eliminate the burden, expense and distraction of further litigation.

In June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Western District of Texas,  United States, et al. ex rel. Urick v. VITAS HME Solutions, Inc. et al., 5:08-cv-0663 (“Urick”).  The U.S. Attorney filed a notice in May 2012 stating that it had decided not to intervene in the case at that time but indicating that it continues to investigate the allegations.  In June 2012, the complaint was unsealed.  The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on allegations of a conspiracy to submit to Medicare and Medicaid false claims involving hospice services for ineligible patients, unnecessary medical supplies, failing to satisfy certain prerequisites for payment, and altering patient records, including backdating patient revocations.  The suit was brought by Barbara Urick, a registered nurse in VITAS’s San Antonio program, against VITAS, certain of its affiliates, and several former VITAS employees, including physicians Justo Cisneros and Antonio Cavasos and nurses Sally Schwenk, Diane Anest, and Edith Reed.  In September 2012 and July 2013, the plaintiff dismissed all claims against the individual defendants.  The complaint was served on the VITAS entities on April 12, 2013.

Also in June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Northern District of Illinois, United States, et al. ex rel. Spottiswood v. Chemed Corp., 1:07-cv-4566 (“Spottiswood”).  In April 2012, the complaint was unsealed.  The U.S. Attorney and Attorney General for the State of Illinois filed notices in April and May 2012, respectively, stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations.  Plaintiff filed an amended complaint in November 2012.  The complaint asserts violations of the federal False Claims Act and the Illinois Whistleblower Reward and Protection Act based on allegations that VITAS fraudulently billed Medicare and Medicaid for providing unwarranted continuous care services.  The suit was brought by Laura Spottiswood, a former part-time pool registered nurse at VITAS, against Chemed, VITAS, and a VITAS affiliate.  The complaint was served on the defendants on April 12, 2013.  On May 29 and June 4, 2013, respectively, the Court granted the government’s motion to partially intervene in Spottiswood and in Urick on the allegations that VITAS submitted or caused to be submitted false or fraudulent claims for continuous care and routine home care on behalf of certain ineligible Medicare beneficiaries.  The Court also transferred them to the U.S. District Court for the Western District of Missouri under docket Nos. 4:13-cv-505 and 4:13-cv-563, respectively.

-16-

On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, United States v. VITAS Hospice Services, LLC, et al., No. 4:13-cv-00449-BCW (the “2013 Action”).  Prior to that date, the Company received various subpoenas from the U.S. Department of Justice and OIG that have been previously disclosed.  The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course.  This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest.  On August 1, 2013, the government filed its First Amended Complaint in the 2013 Action.  The First Amended Complaint changed and supplemented some of the allegations, but did not otherwise expand the causes of action or the nature of the relief sought against VITAS.  The defendants filed a motion to dismiss on September 24, 2013.  The Court denied the motion, except to the extent that claims were filed before July 24, 2002, on September 30, 2014. 

On May 6, 2013, the U.S. District Court for the Western District of Missouri, at the request of the government, unsealed a qui tam complaint against VITAS and VITAS Healthcare Corporation of California, United States ex rel. Charles Gonzales v. VITAS Healthcare Corporation, et al., CV 12-0761-R (“Gonzales”).  The case was transferred from the Central District of California to the Western District of Missouri under docket No. 4:13-cv-344.  The government partially intervened in Gonzales.  The Gonzales complaint alleges that VITAS’ Los Angeles program falsely certified and recertified patients as eligible for the Medicare Hospice Benefit.  It alleges violations of the False Claims Act and seeks treble damages, civil penalties, recovery of costs, attorneys’ fees and expenses, and pre- and post-judgment interest.  

On September 25, 2013, the Court granted a joint motion by the government, the relators, and VITAS to consolidate the Spottiswood,  Urick, and  Gonzales complaints with the 2013 Action.  As a result, the First Amended Complaint will govern the consolidated federal claims brought by the United States and the relators for all purposes.  The relators and VITAS have stipulated that certain non-intervened claims will not be pursued by the relators.  The Spottiswood relator filed an action under the Illinois False Claims Act, The State of Illinois ex rel. Laura Spottiswood v. Chemed Corporation, et al., No. 14 L 2786 in the Circuit Court of Cook County, Illinois on March 6, 2014.  The Court granted the parties’ joint motion to place this case on its stay calendar, pending resolution of the 2013 Action.

VITAS has also received document subpoenas in related state matters.  In February 2010, VITAS received a civil investigative demand (“CID”) from the Texas Attorney General seeking documents from January 1, 2002 through the date of the CID, and interrogatory responses in connection with an investigation of possible fraudulent submission of Medicaid claims for non-qualifying patients and fraudulent shifting of costs from VITAS to the State of Texas and the United States.  The CID requested similar information sought by prior Department of Justice subpoenas, including policy and procedure manuals and information concerning Medicare and Medicaid billing, patient statistics and sales and marketing practices, together with information concerning record-keeping and retention practices, and medical records concerning 117 patients.  In September 2010, VITAS received a third CID from the Texas Attorney General seeking additional documents concerning business plans and results, revocation forms for certain patients, and electronic documents of 10 current and former employees.  In July 2012, VITAS received an investigative subpoena from the Florida Attorney General seeking documents previously produced in the course of prior government investigations as well as, for the period January 1, 2007 through the date of production, billing records and procedures; information concerning business results, plans, and strategies; documents concerning patient eligibility for hospice care; and certain information concerning employees and their compensation.

The net costs incurred related to U.S. v. Vitas and related regulatory matters were $450,000 and a $591,000 credit for the three months ended September 30, 2014 and 2013, respectively.  For the nine months ended September 30, 2014 and 2013, the net costs were $1.6 million and $1.4 million respectively.

-17-

In November 2013, two shareholder derivative lawsuits were filed against the Company’s current and former directors, as well as certain of its officers, both of which are covered by the Company’s commercial insurance.  On November 6, 2013, KBC Asset Management NV filed suit in the United States District Court for the District of Delaware, KBC Asset Management NV, derivatively on behalf of Chemed Corp. v. McNamara, et al., No. 13 Civ. 1854 (LPS) (D. Del.).  It sued Kevin McNamara, Joel Gemunder, Patrick Grace, Thomas Hutton, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, Arthur Tucker, Jr., George Walsh III, Frank Wood, Timothy O’Toole, David Williams and Ernest Mrozek, together with the Company as nominal defendant.  Plaintiff alleges that since at least 2004, Chemed, through VITAS, has submitted or caused the submission of false claims to Medicare.  The suit alleges a claim for breach of fiduciary duty against the individual defendants, and seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.

On November 14, 2013, Mildred A. North filed suit in the United States District Court for the Southern District of Ohio, North, derivatively on behalf of Chemed Corp. v. Kevin McNamara, el al., No. 13 Civ. 833 (MDB) (S.D. Ohio).  She sued Kevin McNamara, David Williams, Timothy O’Toole, Joel Gemunder, Patrick Grace, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, George Walsh III, Frank Wood and Thomas Hutton, together with the Company as nominal defendant.  Plaintiff alleges that, between February 2010 and the present, the individual defendants breached their fiduciary duties as officers and directors of Chemed by, among other things, (a) allegedly causing VITAS to submit improper and ineligible claims to Medicare and Medicaid; and (b) allegedly misrepresenting the state of Chemed’s internal controls.  The suit alleges claims for breach of fiduciary duty, abuse of control and gross mismanagement against the individual defendants.  The complaint also alleges unjust enrichment and insider trading against Messrs. McNamara, Williams and O’Toole.  Plaintiff seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees.

On January 29, 2014 defendants in North filed a motion to transfer that case to Delaware under 28 U.S.C § 1404(a). On February 12, 2014, defendants in KBC filed a motion to dismiss that case pursuant to Federal Rules of Civil Procedure 23.1 and 12(b)(6).  On September 19, 2014, the Ohio court granted defendants’ motion to transfer North to Delaware.  Following that decision and in light of that transfer, on September 29, 2014, the Delaware court denied without prejudice defendants’ motion to dismiss KBC, and referred both cases to Magistrate Judge Burke.  Defendants intend to renew their motion to dismiss the claims and allegations in KBC once it has been determined how these two cases are to proceed.  On October 15, 2014, the plaintiff in KBC filed a motion seeking to consolidate KBC and North, to have plaintiff KBC appointed the sole lead plaintiff and its counsel, Motley Rice, sole lead counsel, and to designate KBC the sole operative complaint.  Plaintiff North has indicated that she does not oppose consolidation of the two cases, but otherwise opposes KBC’s motion with regard to the appointment of lead plaintiff and lead counsel and designation of the operative complaint.  On October 20, 2014, the Court stayed Defendants’ obligation to answer, move, or otherwise respond to the complaints in KBC and North pending further order of the Court.

The Company intends to defend vigorously against the allegations in each of the above lawsuits.  Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, diversion of management time, and related publicity.  Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.

-18-

Results of Operations

Three months ended September 30, 2014 versus  2013 - Consolidated Results

Our service revenues and sales for the third quarter of 2014 increased 5.1% versus services and sales revenues for the third quarter of 2013.  Of this increase, $11.4 million was attributable to VITAS and a $6.1 million increase at Roto-Rooter.  The following chart shows the components of those changes (in thousands):

	Increase/(Decrease)
	Amount		Percent
VITAS
Routine homecare	$	8,489	4.3
Continuous care		2,027	5.6
General inpatient		188	0.8
Medicare cap		679	21.4
Roto-Rooter
Plumbing		996	2.5
Drain cleaning		92	0.3
Contractor operations		697	8.7
Other		4,335	70.0
Total	$	17,503	5.1

The increase in VITAS’ revenues for the third quarter of 2014 versus the third quarter of 2013 was a combination of Medicare reimbursement rates increasing approximately 1.4% and a 2.8% increase in ADC.  In the third quarter of 2014, VITAS recorded a net revenue reduction of $2.5 million related to the recording of Medicare Cap liability for two programs’ 2014 Medicare cap billing limitation which compares to a revenue reduction of $3.2 million in the same quarter of 2013.  The ADC increase was driven by a 2.8% increase in routine homecare and a 3.8% increase in continuous care.  Over 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

The increase in plumbing revenues for the third quarter of 2014 versus 2013 is attributable to a 3.6% decrease in job count, offset by a 6.3% increase in a combination of price and service mix shift.  Drain cleaning revenues for the third quarter of 2014 versus 2013 reflect a 3.9% decrease in the number of jobs performed, offset by a 4.2% increase in a combination of price and service mix shift.  Other Roto-Rooter revenue increased 70.0% mainly as a result of an increase in our water restoration line of business.   Water restoration is the remediation of water and humidity damage after a flood.

The consolidated gross margin was 28.4% in the third quarter of 2014 as compared with 28.7% in the third quarter of 2013.  On a segment basis, VITAS’ gross margin was 22.0% in the third quarter of 2014 and 22.3% in the third quarter of 2013.  The Roto-Rooter segment’s gross margin was 46.9% for the third quarter of 2014 as compared with 47.3% for the third quarter of 2013.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

	Three months ended September 30,
	2014		2013
SG&A expenses before the impact of market gains/(losses) of deferred compensation
plans, long-term incentive compensation, and OIG investigation expenses	$	51,218	$	49,595
Long-term incentive compensation		1,002		55
Net expenses/(cost recovery) related to OIG investigation		450		(591	)
Market value gains/(losses) related to assets held in deferred compensation
trusts		896		(189	)
Total SG&A expenses	$	53,566	$	48,870

SG&A expenses before long-term incentive compensation, expenses related to OIG investigation and the impact of market gains of deferred compensation plans for the third quarter of 2014 were up 3.3% when compared to the third quarter of 2013 as a result of normal salary increases and favorable insurance accrual adjustments in 2013.

-19-

Other operating expenses decreased $11.5 million in the third quarter of 2014 when compared to the third quarter of 2013 as a result of lawsuit settlements at Vitas and Roto-Rooter in 2013 that did not repeat in 2014.

Other income - net comprise (in thousands):

	Three months ended September 30,
	2014			2013
Market value gains/(losses) on assets held in
deferred compensation trusts	$	896		$	(189	)
Loss on disposal of property and equipment		(167	)		(101	)
Interest income - net		(13	)		192
Other		(11	)		8
Total other income - net	$	705		$	(90	)

Our effective income tax rate was 38.4% in the third quarter of 2014 compared to 32.0% for the third quarter of 2013.  This is a result of a $1.8 million credit recorded in the third quarter of 2013 related to the expiration of tax statutes for uncertain tax positions recorded in prior years that did not recur in 2014.

Net income for both periods included the following after-tax items/adjustments that reduced or increased after-tax earnings (in thousands):

	Three months ended September 30,
	2014			2013
VITAS
Litigation settlements	$	-		$	(6,510	)
Net cost recovery/(expenses) related to OIG investigation		(279	)		367
Acquisition expenses		-			(11	)
Roto-Rooter
Net recoveries related to litigation settlements		143			-
Litigation settlements		-			(584	)
Expenses related to litigation settlements		-			(269	)
Acquisition expenses		-			(1	)
Corporate
Stock option expense		(615	)		(1,030	)
Noncash impact of change in accounting for convertible debt		-			(1,375	)
Uncertain tax position adjustments		-			1,782
Long-term incentive compensation		(634	)		(34	)
Expenses related to securities litigation		(88	)		(1	)
Total	$	(1,473	)	$	(7,666	)

Three months ended September 30, 2014 versus 2013 - Segment Results

The change in after-tax earnings for the third quarter of 2014 versus the third quarter of 2013 is due to (in thousands):

	Increase/(Decrease)
	Amount			Percent
VITAS	$	6,985			47.8
Roto-Rooter		1,667			20.4
Corporate		(1,499	)		(28.0	)
	$	7,153			41.0

-20-

Results of Operations

Nine months ended September 30, 2014 versus  2013 - Consolidated Results

Our service revenues and sales for the first nine months of 2014 increased 1.1% versus services and sales revenues for the first nine months of 2013.  Of this increase, $926,000 was attributable to VITAS and an $11.2 million increase at Roto-Rooter.  The following chart shows the components of those changes (in thousands):

	Increase/(Decrease)
	Amount		Percent
VITAS
Routine homecare	$	7,370	1.2
Continuous care		(5,665)	(4.7)
General inpatient		(2,144)	(2.7)
Medicare cap		1,365	43.2
Roto-Rooter
Plumbing		3,687	2.9
Drain cleaning		(2,336)	(2.2)
Contractor operations		2,546	10.4
Other		7,323	39.3
Total	$	12,146	1.1

The increase in VITAS’ revenues for the first nine months of 2014 versus the first nine months of 2013 was a combination of Medicare reimbursement rates increasing approximately 1.4%, offset by a 2.0% decline due to sequestration (which was effective May 1, 2013), an ADC increase of 0.3%, and geographical and level of care mix shift.  In the first nine months of 2014, VITAS recorded a revenue adjustment of $1.8 million related to eliminating the Medicare cap billing limitation recorded in the fourth quarter of 2013 for one program and by the recording of Medicare cap billing limitations for two programs’ liability for the 2014 Medicare cap year.  This compares with a $3.2 million Medicare cap liability recorded in the first nine months of 2013.  The ADC increase was driven by a 0.7% increase in routine homecare, a decrease of 5.3% in continuous care and a decrease of 2.5% in general inpatient.  Over 90% of VITAS’ service revenues for the period were from Medicare and Medicaid.

The increase in plumbing revenues for the first nine months of 2014 versus 2013 is attributable to a 1.1% increase in job count, and a 1.8% increase in price and service mix shift.  Drain cleaning revenues for the first nine months of 2014 versus 2013 reflect a 6.5% decrease in the number of jobs performed, offset by a 4.3% increase in a combination of price and service mix shift.  Other Roto-Rooter revenue increased 39.3% as a result of a increase in our water restoration line of business.  Water restoration is the remediation of water and humidity damage after a flood.

The consolidated gross margin was 28.4% in the first nine months of 2014 which is essentially flat when compared with the first nine months of 2013.  On a segment basis, VITAS’ gross margin was 21.7% in the first nine months of 2014 and 21.9% in the first nine months of 2013.  The Roto-Rooter segment’s gross margin was 46.7% for the first nine months of 2014 as compared with 46.9% for the first nine months of 2013.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

	Nine months ended September 30,
	2014		2013
SG&A expenses before the impact of market gains of deferred compensation
plans, long-term incentive compensation, and OIG investigation expenses	$	156,582	$	152,586
Long-term incentive compensation		1,988		1,161
Expenses related to OIG investigation		1,608		1,444
Market value gains related to assets held in
deferred compensation trusts		2,708		2,346
Total SG&A expenses	$	162,886	$	157,537

-21-

SG&A expenses before long-term incentive compensation, expenses related to OIG investigation and the impact of market gains of deferred compensation plans for the first nine months of 2014 were up 2.6% when compared to the first nine months of 2013 as a result of normal salary increases and favorable insurance accrual adjustments in 2013.

Other operating expenses decreased $26.2 million in the first nine months of 2014 when compared to the first nine months of 2013 as a result of lawsuit settlements at Vitas and Roto-Rooter in 2013 that did not repeat in 2014.

Other income - net comprise (in thousands):

	Nine months ended September 30,
	2014			2013
Market value gains on assets held in deferred
compensation trusts	$	2,708		$	2,346
Loss on disposal of property and equipment		(493	)		(180	)
Interest income - net		(5	)		1,165
Other		67			(19	)
Total other income - net	$	2,277		$	3,312

Our effective income tax rate was 38.7% in the first nine months of 2014 when compared to 36.8% in the first nine months of 2013.  This increase is a result of a $1.8 million credit recorded in 2013 related to the expiration of tax statutes for uncertain tax positions recorded in prior years.

Net income for both periods included the following after-tax items/adjustments that reduced or increased after-tax earnings (in thousands):

	Nine Months Ended September 30,
	2014			2013
VITAS
Litigation settlements	$	-		$	(6,510	)
Expenses related to litigation settlements		(70	)		-
Legal expenses of OIG investigation		(997	)		(895	)
Acquisition expenses		(1	)		(23	)
Roto-Rooter
Net recoveries related to litigation settlements		6			-
Litigation settlements		-			(9,551	)
Expenses related to litigation settlements		-			(699	)
Expenses of severance arrangements		-			(184	)
Acquisition expenses		-			(2	)
Corporate
Stock option expense		(2,159	)		(2,993	)
Noncash impact of change in accounting for convertible debt		(2,143	)		(4,046	)
Uncertain tax position adjustments		-			1,782
Long-term incentive compensation		(1,258	)		(734	)
Expenses of securities litigation		(207	)		(3	)
Loss on extinguishment of debt		-			(294	)
Total	$	(6,829	)	$	(24,152	)

-22-

Nine months ended September 30, 2014 versus 2013 - Segment Results

The change in after-tax earnings for the first nine months of 2014 versus the first nine months of 2013 is due to (in thousands):

	Increase/(Decrease)
	Amount			Percent
VITAS	$	5,408			9.8
Roto-Rooter		11,381			59.2
Corporate		(1,585	)		(7.9	)
	$	15,204			28.0

-23-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2014
(in thousands)(unaudited)
	VITAS			Roto-Rooter			Corporate			Chemed Consolidated
2014 (a)
Service revenues and sales	$	265,384		$	93,005		$	-		$	358,389
Cost of services provided and goods sold		207,105			49,340			-			256,445
Selling, general and administrative expenses		20,224			25,682			7,660			53,566
Depreciation		4,530			2,772			148			7,450
Amortization		205			114			398			717
Total costs and expenses		232,064			77,908			8,206			318,178
Income/(loss) from operations		33,320			15,097			(8,206	)		40,211
Interest expense		(55	)		(87	)		(838	)		(980	)
Intercompany interest income/(expense)		1,660			760			(2,420	)		-
Other income/(expense)—net		(189	)		(2	)		896			705
Income/(expense) before income taxes		34,736			15,768			(10,568	)		39,936
Income taxes		(13,143	)		(5,920	)		3,712			(15,351	)
Net income/(loss)	$	21,593		$	9,848		$	(6,856	)	$	24,585
(a) The following amounts are included in net income (in thousands):
											Chemed
	VITAS				Roto-Rooter			Corporate			Consolidated
Pretax benefit/(cost):
Stock option expense	$	-		$	-		$	(977	)	$	(977	)
Long-term incentive compensation		-			-			(1,002	)		(1,002	)
Net recoveries related to litigation settlements		-			234			-			234
Expenses related to securities litigation		-			-			(138	)		(138	)
Expenses related to OIG investigation		(450	)		-			-			(450	)
Total	$	(450	)	$	234		$	(2,117	)	$	(2,333	)
											Chemed
	VITAS				Roto-Rooter			Corporate			Consolidated
After-tax benefit/(cost):
Stock option expense	$	-		$	-		$	(615	)	$	(615	)
Long-term incentive compensation		-			-			(634	)		(634	)
Net recoveries related to litigation settlements		-			143			-			143
Expenses related to securities litigation		-			-			(88	)		(88	)
Expenses related to OIG investigation		(279	)		-			-			(279	)
Total	$	(279	)	$	143		$	(1,337	)	$	(1,473	)

-24-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2013
(in thousands)(unaudited)
		VITAS			Roto-Rooter			Corporate			Chemed Consolidated
2013 (a)
Service revenues and sales	$	254,001		$	86,885		$	-		$	340,886
Cost of services provided and goods sold		197,387			45,797			-			243,184
Selling, general and administrative expenses		18,637			25,009			5,224			48,870
Depreciation		4,545			2,292			134			6,971
Amortization		538			151			501			1,190
Other operating expenses		10,500			961			-			11,461
Total costs and expenses		231,607			74,210			5,859			311,676
Income/(loss) from operations		22,394			12,675			(5,859	)		29,210
Interest expense		(48	)		(82	)		(3,370	)		(3,500	)
Intercompany interest income/(expense)		1,231			579			(1,810	)		-
Other income/(expense)—net		73			8			(171	)		(90	)
Income/(expense) before income taxes		23,650			13,180			(11,210	)		25,620
Income taxes		(9,042	)		(4,999	)		5,853			(8,188	)
Net income/(loss)	$	14,608		$	8,181		$	(5,357	)	$	17,432
(a) The following amounts are included in net income (in thousands):
	VITAS			Roto-Rooter			Corporate			Chemed Consolidated
Pretax benefit/(cost):
Stock option expense	$	-		$	-		$	(1,629	)	$	(1,629	)
Noncash impact of accounting for convertible debt		-			-			(2,174	)		(2,174	)
Long-term incentive compensation		-			-			(55	)		(55	)
Litigation settlements		(10,500	)		(961	)		-			(11,461	)
Expenses related to litigation settlements		-			(443	)		-			(443	)
Expenses related to securities litigation		-			-			(1	)		(1	)
Acquisition expenses		(18	)		(3	)		-			(21	)
Net cost recovery related to OIG investigation		591			-			-			591
Total	$	(9,927	)	$	(1,407	)	$	(3,859	)	$	(15,193	)
	VITAS			Roto-Rooter			Corporate			Chemed Consolidated
After-tax benefit/(cost):
Stock option expense	$	-		$	-		$	(1,030	)	$	(1,030	)
Noncash impact of accounting for convertible debt		-			-			(1,375	)		(1,375	)
Long-term incentive compensation		-			-			(34	)		(34	)
Litigation settlements		(6,510	)		(584	)		-			(7,094	)
Uncertain tax position adjustments		-			-			1,782			1,782
Expenses related to litigation settlements		-			(269	)		-			(269	)
Expenses related to securities litigation		-			-			(1	)		(1	)
Acquisition expenses		(11	)		(1	)		-			(12	)
Net cost recovery related to OIG investigation		367			-			-			367
Total	$	(6,154	)	$	(854	)	$	(658	)	$	(7,666	)

-25-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2014
(in thousands)(unaudited)
		VITAS			Roto-Rooter			Corporate			Chemed Consolidated
2014 (a)
Service revenues and sales	$	789,822		$	287,049		$	-		$	1,076,871
Cost of services provided and goods sold		618,315			152,956			-			771,271
Selling, general and administrative expenses		62,939			78,569			21,378			162,886
Depreciation		13,709			7,732			430			21,871
Amortization		829			397			1,235			2,461
Total costs and expenses		695,792			239,654			23,043			958,489
Income/(loss) from operations		94,030			47,395			(23,043	)		118,382
Interest expense		(167	)		(295	)		(6,762	)		(7,224	)
Intercompany interest income/(expense)		4,520			2,090			(6,610	)		-
Other income/(expense)—net		(577	)		137			2,717			2,277
Income/(expense) before income taxes		97,806			49,327			(33,698	)		113,435
Income taxes		(37,161	)		(18,728	)		11,976			(43,913	)
Net income/(loss)	$	60,645		$	30,599		$	(21,722	)	$	69,522
(a) The following amounts are included in net income (in thousands):
		VITAS			Roto-Rooter			Corporate			Chemed Consolidated
Pretax benefit/(cost):
Stock option expense	$	-		$	-		$	(3,430	)	$	(3,430	)
Noncash impact of accounting for convertible debt		-			-			(3,389	)		(3,389	)
Long-term incentive compensation		-			-			(1,988	)		(1,988	)
Net recoveries/(expenses) related to litigation settlements		(113	)		9			-			(104	)
Expenses related to securities litigation		-			-			(327	)		(327	)
Acquisition expenses		(1	)		-			-			(1	)
Expenses related to OIG investigation		(1,608	)		-			-			(1,608	)
Total	$	(1,722	)	$	9		$	(9,134	)	$	(10,847	)
	VITAS			Roto-Rooter			Corporate			Chemed Consolidated
After-tax benefit/(cost):
Stock option expense	$	-		$	-		$	(2,159	)	$	(2,159	)
Noncash impact of accounting for convertible debt		-			-			(2,143	)		(2,143	)
Long-term incentive compensation		-			-			(1,258	)		(1,258	)
Net recoveries/(expenses) related to litigation settlements		(70	)		6			-			(64	)
Expenses related to securities litigation		-			-			(207	)		(207	)
Acquisition expenses		(1	)		-			-			(1	)
Expenses related to OIG investigation		(997	)		-			-			(997	)
Total	$	(1,068	)	$	6		$	(5,767	)	$	(6,829	)

-26-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENT OF INCOME
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2013
(in thousands)(unaudited)
	VITAS			Roto-Rooter			Corporate			Chemed Consolidated
2013 (a)
Service revenues and sales	$	788,896		$	275,829		$	-		$	1,064,725
Cost of services provided and goods sold		616,334			146,516			-			762,850
Selling, general and administrative expenses		61,304			76,901			19,332			157,537
Depreciation		13,579			6,685			401			20,665
Amortization		1,564			454			1,480			3,498
Other operating expenses		10,500			15,721			-			26,221
Total costs and expenses		703,281			246,277			21,213			970,771
Income/(loss) from operations		85,615			29,552			(21,213	)		93,954
Interest expense		(145	)		(239	)		(10,907	)		(11,291	)
Intercompany interest income/(expense)		2,940			1,443			(4,383	)		-
Other income/(expense)—net		878			42			2,392			3,312
Income/(expense) before income taxes		89,288			30,798			(34,111	)		85,975
Income taxes		(34,051	)		(11,580	)		13,974			(31,657	)
Net income/(loss)	$	55,237		$	19,218		$	(20,137	)	$	54,318
(a) The following amounts are included in net income (in thousands):
		VITAS			Roto-Rooter			Corporate			Chemed Consolidated
Pretax benefit/(cost):
Stock option expense	$	-		$	-		$	(4,732	)	$	(4,732	)
Noncash impact of accounting for convertible debt		-			-			(6,397	)		(6,397	)
Long-term incentive compensation		-			-			(1,161	)		(1,161	)
Expenses of severance arrangements		-			(302	)		-			(302	)
Loss on extinguishment of debt		-			-			(465	)		(465	)
Litigation settlements		(10,500	)		(15,721	)		-			(26,221	)
Expenses related to litigation settlements		-			(1,151	)		-			(1,151	)
Expenses related to securities litigation		-			-			(4	)		(4	)
Acquisition expenses		(38	)		(4	)		-			(42	)
Expenses of OIG investigation		(1,444	)		-			-			(1,444	)
Total	$	(11,982	)	$	(17,178	)	$	(12,759	)	$	(41,919	)
		VITAS			Roto-Rooter			Corporate			Chemed Consolidated
After-tax benefit/(cost):
Stock option expense	$	-		$	-		$	(2,993	)	$	(2,993	)
Noncash impact of accounting for convertible debt		-			-			(4,046	)		(4,046	)
Long-term incentive compensation		-			-			(734	)		(734	)
Uncertain tax position position adjustments		-			-			1,782			1,782
Expenses of severance arrangements		-			(184	)		-			(184	)
Loss on extinguishment of debt		-			-			(294	)		(294	)
Litigation settlements		(6,510	)		(9,551	)		-			(16,061	)
Expenses related to litigation settlements		-			(699	)		-			(699	)
Expenses related to securities litigation		-			-			(3	)		(3	)
Acquisition expenses		(23	)		(2	)		-			(25	)
Expenses of OIG investigation		(895	)		-			-			(895	)
Total	$	(7,428	)	$	(10,436	)	$	(6,288	)	$	(24,152	)

-27-

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA
Chemed Corporation and Subsidiary Companies
(in thousands)
For the three months ended September 30, 2014		VITAS			Roto-Rooter			Corporate			Chemed Consolidated
Net income/(loss)	$	21,593		$	9,848		$	(6,856	)	$	24,585
Add/(deduct):								-
Interest expense		55			87			838			980
Income taxes		13,143			5,920			(3,712	)		15,351
Depreciation		4,530			2,772			148			7,450
Amortization		205			114			398			717
EBITDA		39,526			18,741			(9,184	)		49,083
Add/(deduct):
Intercompany interest expense/(income)		(1,660	)		(760	)		2,420			-
Interest income		23			(9	)		(1	)		13
Expenses related to OIG investigation		450			-			-			450
Net recoveries related to litigation settlements		-			(234	)		-			(234	)
Advertising cost adjustment		-			(483	)		-			(483	)
Stock option expense		-			-			977			977
Long-term incentive compensation		-			-			1,002			1,002
Expenses related to securities litigation		-			-			138			138
Adjusted EBITDA	$	38,339		$	17,255		$	(4,648	)	$	50,946
For the three months ended September 30, 2013		VITAS			Roto-Rooter			Corporate			Chemed Consolidated
Net income/(loss)	$	14,608		$	8,181		$	(5,357	)	$	17,432
Add/(deduct):
Interest expense		48			82			3,370			3,500
Income taxes		9,042			4,999			(5,853	)		8,188
Depreciation		4,545			2,292			134			6,971
Amortization		538			151			501			1,190
EBITDA		28,781			15,705			(7,205	)		37,281
Add/(deduct):
Intercompany interest expense/(income)		(1,231	)		(579	)		1,810			-
Interest income		(163	)		(10	)		(19	)		(192	)
Expenses related to OIG investigation		(591	)		-			-			(591	)
Acquisition expenses		18			3			-			21
Litigation settlements		10,500			961			-			11,461
Advertising cost adjustment		-			(369	)		-			(369	)
Expenses related to litigation settlements		-			443			-			443
Long-term incentive compensation		-			-			55			55
Stock option expense		-			-			1,629			1,629
Expenses of securities litigation		-			-			1			1
Adjusted EBITDA	$	37,314		$	16,154		$	(3,729	)	$	49,739

-28-

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA
Chemed Corporation and Subsidiary Companies
(in thousands)													Chemed
For the nine months ended September 30, 2014	VITAS				Roto-Rooter				Corporate				Consolidated
Net income/(loss)		$	60,645			$	30,599			$	(21,722	)		$	69,522
Add/(deduct):
Interest expense			167				295				6,762				7,224
Income taxes			37,161				18,728				(11,976	)			43,913
Depreciation			13,709				7,732				430				21,871
Amortization			829				397				1,235				2,461
EBITDA			112,511				57,751				(25,271	)			144,991
Add/(deduct):
Intercompany interest expense/(income)			(4,520	)			(2,090	)			6,610				-
Interest income			43				(28	)			(10	)			5
Expenses related to OIG investigation			1,608				-				-				1,608
Acquisition expenses			1				-				-				1
Net expenses/(recoveries) related to litigation settlements			113				(9	)			-				104
Advertising cost adjustment			-				(1,623	)			-				(1,623	)
Stock option expense			-				-				3,430				3,430
Long-term incentive compensation			-				-				1,988				1,988
Expenses related to securities litigation			-				-				327				327
Adjusted EBITDA		$	109,756			$	54,001			$	(12,926	)		$	150,831
													Chemed
For the nine months ended September 30, 2013	VITAS				Roto-Rooter				Corporate				Consolidated
Net income/(loss)		$	55,237			$	19,218			$	(20,137	)		$	54,318
Add/(deduct):
Interest expense			145				239				10,907				11,291
Income taxes			34,051				11,580				(13,974	)			31,657
Depreciation			13,579				6,685				401				20,665
Amortization			1,564				454				1,480				3,498
EBITDA			104,576				38,176				(21,323	)			121,429
Add/(deduct):
Intercompany interest expense/(income)			(2,940	)			(1,443	)			4,383				-
Interest income			(1,051	)			(66	)			(48	)			(1,165	)
Expenses related to OIG investigation			1,444				-				-				1,444
Acquisition expenses			38				4				-				42
Litigation settlement			10,500				15,721				-				26,221
Advertising cost adjustment			-				(1,343	)			-				(1,343	)
Cost of severance arrangements			-				302				-				302
Expenses related to litigation settlements			-				1,151				-				1,151
Long-term incentive compensation			-				-				1,161				1,161
Stock option expense			-				-				4,732				4,732
Expenses related to securities litigation			-				-				4				4
Adjusted EBITDA		$	112,567			$	52,502			$	(11,091	)		$	153,978

-29-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
RECONCILIATION OF ADJUSTED NET INCOME
(in thousands, except per share data)(unaudited)
	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014		2013
Net income as reported	$	24,585		$	17,432		$	69,522	$	54,318
Add/(deduct) after-tax cost of:
Net expenses/(recoveries) related to litigation settlements		(143	)		269			64		699
Uncertain tax position adjustments		-			(1,782	)		-		(1,782	)
Additional interest expense resulting from the change in accounting
for the conversion feature of the convertible notes		-			1,375			2,143		4,046
Stock option expense		615			1,030			2,159		2,993
Net expenses/(cost recovery) of OIG investigation		279			(367	)		997		895
Long-term incentive compensation		634			34			1,258		734
Litigation settlements		-			7,094			-		16,061
Acquisition expenses		-			12			1		25
Loss on extinguishment of debt		-			-			-		294
Expenses of severance arrangements		-			-			-		184
Expenses related to securities litigation		88			1			207		3
Adjusted net income	$	26,058		$	25,098		$	76,351	$	78,470
Diluted Earnings Per Share As Reported
Net income	$	1.39		$	0.94		$	3.87	$	2.89
Average number of shares outstanding		17,627			18,522			17,968		18,824
Adjusted Diluted Earnings Per Share
Adjusted net income	$	1.48		$	1.36		$	4.28	$	4.17
Adjusted average number of shares outstanding*		17,627			18,522			17,833		18,824

* Adjusted diluted average shares outstanding excludes the estimated dilutive impact of the Convertible Notes prior to conversion of these Notes on May 15, 2014 (135,000 shares for the nine months ended September 30, 2014) as this impact was entirely offset upon the exercise of the note hedges on May 15, 2014.

-30-

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)
	Three Months Ended September 30,						Nine Months Ended September 30,
OPERATING STATISTICS	2014			2013			2014			2013
Net revenue ($000)
Homecare	$	204,965		$	196,476		$	600,780		$	593,410
Inpatient		25,012			24,824			77,037			79,181
Continuous care		37,907			35,880			113,801			119,466
Total before Medicare cap allowance	$	267,884		$	257,180		$	791,618		$	792,057
Medicare cap allowance		(2,500	)		(3,179	)		(1,796	)		(3,161	)
Total	$	265,384		$	254,001		$	789,822		$	788,896
Net revenue as a percent of total before Medicare cap allowances
Homecare		76.5	%		76.4	%		75.9	%		74.9	%
Inpatient		9.3			9.7			9.7			10.0
Continuous care		14.2			14.0			14.5			15.2
Total before Medicare cap allowance		100.0			100.1			100.1			100.1
Medicare cap allowance		(0.9	)		(1.3	)		(0.2	)		(0.4	)
Total		99.1	%		98.8	%		99.9	%		99.7	%
Average daily census (days)
Homecare		10,662			10,373			10,562			10,482
Nursing home		2,999			2,911			2,940			2,928
Routine homecare		13,661			13,284			13,502			13,410
Inpatient		417			417			429			440
Continuous care		561			540			568			600
Total		14,639			14,241			14,499			14,450
Total Admissions		15,653			14,555			47,777			47,413
Total Discharges		15,460			14,971			47,139			47,603
Average length of stay (days)		83.7			82.2			82.4			81.3
Median length of stay (days)		15.0			16.0			15.0			15.0
ADC by major diagnosis
Neurological		32.7	%		37.8	%		35.0	%		36.8	%
Cancer		17.3			17.1			17.4			17.0
Cardio		17.6			13.9			16.6			12.8
Respiratory		8.0			7.8			7.9			7.5
Other		24.4			23.4			23.1			25.9
Total		100.0	%		100.0	%		100.0	%		100.0	%
Admissions by major diagnosis
Neurological		18.2			21.0	%		20.6	%		20.3	%
Cancer		34.0			34.4			33.3			33.0
Cardio		15.2			13.8			14.8			13.0
Respiratory		9.1			9.0			9.5			9.3
Other		23.5			21.8			21.8			24.4
Total		100.0	%		100.0	%		100.0	%		100.0	%
Direct patient care margins
Routine homecare		53.8	%		52.5	%		53.4	%		52.2	%
Inpatient		4.9			1.7			5.4			5.6
Continuous care		17.4			14.8			17.2			15.8
Homecare margin drivers (dollars per patient day)
Labor costs	$	53.65		$	54.64		$	54.31		$	55.61
Drug costs		6.64			7.52			7.04			7.55
Home medical equipment		6.09			6.67			6.07			6.69
Medical supplies		3.22			2.83			3.20			2.96
Inpatient margin drivers (dollars per patient day)
Labor costs	$	345.18		$	354.09		$	344.05		$	339.84
Continuous care margin drivers (dollars per patient day)
Labor costs	$	584.99		$	594.25		$	586.60		$	592.15
Bad debt expense as a percent of revenues		1.0	%		0.9	%		1.0	%		0.9	%
Accounts receivable --
Days of revenue outstanding- excluding unapplied Medicare payments		38.1			34.6		n.a			n.a
Days of revenue outstanding- including unapplied Medicare payments		36.3			21.9		n.a			n.a

-31-

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made.  These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements.  Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends.  In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters.  Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved.  Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.

Item 3.   Quantitative and Qualitative Disclosures about Market Risk

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit.  At September 30, 2014, the Company had $173.6 million of variable rate debt outstanding.  For each $10 million dollars borrowed under the credit facility, an increase or decrease of 100 basis points (1% point), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

Item 4.    Controls and Procedures

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report.  Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.  There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.    Legal Proceedings

For information regarding the Company’s legal proceedings, see note 10, Legal and Regulatory Matters, under Part I, Item I of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors

There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

-32-

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

                 Item 2(c). Purchases of Equity Securities by Issuer and Affiliated Purchasers

The following table shows the activity related to our share repurchase program for the first nine months of 2014:

	Total Number		Weighted		Cumulative Shares		Dollar Amount
	of Shares		Price Paid Per		Repurchased Under		Remaining Under
	Repurchased		Share		the Program		The Program
February 2011 Program
January 1 through January 31, 2014		-	$	-		4,891,885	$	21,828,041
February 1 through February 28, 2014		132,934		82.50		5,024,819		110,860,736
March 1 through March 31, 2014		250,000		88.06		5,274,819	$	88,845,624
First Quarter Total		382,934	$	86.13
April 1 through April 30, 2014		-	$	-		5,274,819	$	88,845,624
May 31 through May 31, 2014		300,000		85.04		5,574,819		63,334,823
June 1 through June 30, 2014		-		-		5,574,819	$	63,334,823
Second Quarter Total		300,000	$	85.04
July 1 through July 31, 2014		-	$	-		5,574,819	$	63,334,823
August 1 through August 31, 2014		358,178		101.35		5,932,997		27,032,332
September 1 through September 30, 2014		41,822		103.00		5,974,819	$	22,724,648
Third Quarter Total		400,000	$	101.53
On February 21, 2014, our Board of Directors authorized an additional $100 million under the February 2011 Repurchase

Item 3.	Defaults Upon Senior Securities
	None
Item 4.	Mine Safety Disclosures
	None
Item 5.	Other Information
	None

-33-

Item 6.   Exhibits

Exhibit No.	Description
31.1	Certification by Kevin J. McNamara pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.
31.2	Certification by David P. Williams pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange  Act of 1934.
31.3	Certification by Arthur V. Tucker, Jr. pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.
32.1	Certification by Kevin J. McNamara pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification by David P. Williams pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.3	Certification by Arthur V. Tucker, Jr. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema
101.CAL	XBRL Taxonomy Extension Calculation Linkbase
101.DEF	XBRL Taxonomy Extension Definition Linkbase
101.LAB	XBRL Taxonomy Extension Label Linkbase
101.PRE	XBRL Taxonomy Extension Presentation Linkbase

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Chemed Corporation
			(Registrant)
Dated:	November 5, 2014	By:	/s/ Kevin J. McNamara
			Kevin J. McNamara
			(President and Chief Executive Officer)
Dated:	November 5, 2014	By:	/s/ David P. Williams
			David P. Williams
			(Executive Vice President and Chief Financial Officer)
Dated:	November 5, 2014	By:	/s/ Arthur V. Tucker, Jr.
			Arthur V. Tucker, Jr.
			(Vice President and Controller)

-34-

EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934

I, Kevin J. McNamara, certify that:

1.  I have reviewed this quarterly report on Form 10-Q of Chemed Corporation (“registrant”);

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.  The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)  evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter  (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors or persons performing the equivalent function:

a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	November 5, 2014	/s/ Kevin J. McNamara
		Kevin J. McNamara
		(President and Chief
		Executive Officer)

E-1

EX-31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULES 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934

I, David P. Williams, certify that:

1.  I have reviewed this quarterly report on Form 10-Q of Chemed Corporation (“registrant”);

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.  The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)  evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors or persons performing the equivalent function:

a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	November 5, 2014	/s/ David P. Williams
		David P. Williams
		(Executive Vice President and Chief Financial Officer)

E-2

EX-31.3

EXHIBIT 31.3

CERTIFICATION PURSUANT TO RULES 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934

I, Arthur V. Tucker, Jr., certify that:

1.  I have reviewed this quarterly report on Form 10-Q of Chemed Corporation (“registrant”);

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.  The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles,

c)  evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)  disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors or persons performing the equivalent function:

a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	November 5, 2014	/s/ Arthur V. Tucker, Jr.
		Arthur V. Tucker, Jr.
		(Vice President and
		Controller)

E-3

EX-32.1

 EXHIBIT 32.1

CERTIFICATION BY KEVIN J. MCNAMARA

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as President and Chief Executive Officer of Chemed Corporation (“Company”), does hereby certify that:

1) the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2014 (“Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	November 5, 2014	/s/ Kevin J. McNamara
		Kevin J. McNamara
		(President and Chief
		Executive Officer)

E-4

EX-32.2

 EXHIBIT 32.2

CERTIFICATION BY DAVID P. WILLIAMS

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as Executive Vice President and Chief Financial Officer of Chemed Corporation (“Company”), does hereby certify that:

1) the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2014 (“Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	November 5, 2014	/s/ David P. Williams
		David P. Williams
		(Executive Vice President and Chief Financial
		Officer)

E-5

EX-32.3

 EXHIBIT 32.3

CERTIFICATION BY ARTHUR V. TUCKER, JR.

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as Vice President and Controller of Chemed Corporation (“Company”), does hereby certify that:

1) the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2014 (“Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	November 5, 2014	/s/ Arthur V. Tucker, Jr.
		Arthur V. Tucker, Jr.
		(Vice President and  Controller)

E-6

XML

Long-Term Debt (Financial Debt Covenants) (Details) (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2014
Long-Term Debt [Abstract]
Leverage Ratio (Consolidated Indebtedness/Consolidated Adj. EBITDA), Requirement	3.50
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges), Requirement	1.50
Annual Operating Lease Commitment, Requirement	$ 50.0

XML

Financial Instruments (Carrying Value, Fair Value And Hierarchy Of Financial Instruments) (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Carrying Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mutual fund investments of deferred compensation plans held in trust	$ 47,780	$ 42,465
Long-term debt	173,550	183,564
Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mutual fund investments of deferred compensation plans held in trust	47,780	42,465
Long-term debt		193,032
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt	$ 173,550

XML

Concentration Of Risk (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Concentration Of Risk [Abstract]
Period of renewal of pharmacy services agreements			3 years
Number of days prior written notice to cancel agreements			30 days
VITAS made purchases from OCR	$ 8.8	$ 9.7	$ 26.5	$ 29.3
Percentage of concentration risk services represent from vendor	90.00%	90.00%	90.00%	90.00%

XML

Segments (Service Revenues And Sales And After-Tax Earnings By Business Segment) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]
Total service revenues and sales	$ 358,389	$ 340,886	$ 1,076,871	$ 1,064,725
Net income	24,585	17,432	69,522	54,318
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total service revenues and sales	358,389	340,886	1,076,871	1,064,725
Net income	31,441	22,789	91,244	74,455
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Net income	(6,856)	(5,357)	(21,722)	(20,137)
Segment VITAS [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total service revenues and sales	265,384	254,001	789,822	788,896
Net income	21,593	14,608	60,645	55,237
Segment Roto-Rooter [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total service revenues and sales	93,005	86,885	287,049	275,829
Net income	$ 9,848	$ 8,181	$ 30,599	$ 19,218

XML

Other Income - Net (Tables)

9 Months Ended

Sep. 30, 2014

Other Income - Net [Abstract]

Schedule Of Other Income - Net

	Three months ended September 30,				Nine months ended September 30,
	2014		2013		2014		2013
Market value gains/(losses) on assets held in
deferred compensation trust	$	896	$	(189)	$	2,708	$	2,346
Loss on disposal of property and equipment		(167)		(101)		(493)		(180)
Interest income - net		(13)		192		(5)		1,165
Other - net		(11)		8		67		(19)
Total other income - net	$	705	$	(90)	$	2,277	$	3,312

XML

Independent Contractor Operations (Narrative) (Details) (USD $) In Millions, unless otherwise specified				9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014 Settlements of Roto-Rooter segment [Member] item	Sep. 30, 2014 Maximum [Member]	Sep. 30, 2014 Minimum [Member]
Independent Contractor Operations [Line Items]
Independent contractors with sublicenses			68
Notes receivable from independent contractors	$ 1.0	$ 1.5
Interest rates on loans				8.00%	0.00%
Terms of the loans to independent contractors, years				5 years	2 months

XML

Long-Term Debt (Debt Outstanding) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Total	$ 173,550,000
Current portion of term loan and revolving loan	(20,425,000)	(183,564,000)
Long-term debt	153,125,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Total	74,800,000
Medium-term Notes [Member]
Debt Instrument [Line Items]
Total	$ 98,750,000

XML

Cash Overdrafts And Cash Equivalents (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Cash Overdrafts And Cash Equivalents [Abstract]
Cash overdrafts included in accounts payable		$ 806
Cash equivalents	$ 68	$ 23,100
Cash equivalents weighted average rate of return	0.09%	0.08%

XML

Earnings Per Share

9 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Earnings Per Share

4.  Earnings per Share

Earnings per share (“EPS”) are computed using the weighted average number of shares of capital stock outstanding.  Earnings and diluted earnings per share are computed as follows (in thousands, except per share data):

			Net Income
For the Three Months Ended September 30,		Income		Shares	Earnings per Share
2014
	Earnings	$	24,585	17,039	$	1.44
	Dilutive stock options		-	416
	Nonvested stock awards		-	151
	Impact of warrants outstanding		-	21
	Diluted earnings	$	24,585	17,627	$	1.39
2013
	Earnings	$	17,432	18,184	$	0.96
	Dilutive stock options		-	235
	Nonvested stock awards		-	103
	Diluted earnings	$	17,432	18,522	$	0.94

			Net Income
For the Nine Months Ended September 30,		Income		Shares	Earnings per Share
2014
	Earnings	$	69,522	17,263	$	4.03
	Dilutive stock options		-	402
	Nonvested stock awards		-	147
	Conversion of Notes and impact of warrants outstanding		-	156
	Diluted earnings	$	69,522	17,968	$	3.87
2013
	Earnings	$	54,318	18,436	$	2.95
	Dilutive stock options		-	287
	Nonvested stock awards		-	101
	Diluted earnings	$	54,318	18,824	$	2.89

For the three and nine-month periods ended September 30, 2014, no stock options were excluded from the computation of diluted earnings per share because they would have been anti-dilutive. For the three and nine-month periods ended September 30, 2013, 434,000 and 31,000 stock options, respectively, were excluded from the computation of diluted earnings per share.

Diluted earnings per share was impacted by the issuance of 249,000 shares of capital stock under the conversion feature of our 1.875% Senior Convertible Notes (the “Notes”) on May 15, 2014.  The dilutive impact of this conversion feature for the first nine months of 2014 was 135,000 shares.

At the time we issued the Notes, as discussed in Note 5 below, we also sold warrants for the right to purchase approximately 2,477,000 Chemed shares in the future.  During the quarter ended June 30, 2014, we settled these warrants with one counterparty representing half of the total warrants issued for $2.6 million.  The amount paid was recorded as an adjustment to paid-in capital.   The remaining half of the sold warrants remain outstanding and mature ratably from August 15 through December 8, 2014.  The dilutive impact of the warrants was 21,000 shares for the three and nine months periods ended September 30, 2014.

XML

Independent Contractor Operations (Schedule Of Independent Contractors) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Independent Contractor Operations [Abstract]
Revenues	$ 8,751	$ 8,054	$ 26,964	$ 24,418
Pretax profits	$ 4,946	$ 4,243	$ 15,341	$ 13,015

XML

Capital Stock Repurchase Plan Transactions (Tables)

9 Months Ended

Sep. 30, 2014

Capital Stock Repurchase Plan Transactions [Abstract]

Schedule Of Capital Stock Repurchases

	Three months ended September 30,				Nine months ended September 30,
	2014		2013		2014		2013
Shares repurchased		400,000		1,032,754		1,082,934		1,313,455
Weighted average price per share	$	101.53	$	68.91	$	91.51	$	68.23

XML

Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2014

Financial Instruments [Abstract]

Carrying Value, Fair Value And Hierarchy Of Financial Instruments

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of          

September 30, 2014 (in thousands):

				Fair Value Measure
		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Mutual fund investments of deferred
compensation plans held in trust	$	47,780	$	47,780	$	-	$	-
Long-term debt		173,550		-		173,550		-

All outstanding long-term debt is at a floating interest rate tied to LIBOR. Therefore, the carrying amount is a reasonable estimation of fair value.

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of      December 31, 2013 (in thousands):

				Fair Value Measure
		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Mutual fund investments of deferred
compensation plans held in trust	$	42,465	$	42,465	$	-	$	-
Long-term debt		183,564		193,032		-		-

XML

Retirement Plans (Schedule Of Expenses For Retirement, Profit-Sharing Plans, Excess Benefit Plans And Other Similar Plans) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Retirement Plans [Abstract]
Defined contribution plans	$ 3,635	$ 2,098	$ 10,856	$ 9,796

XML

Revenue Recognition (Narrative) (Details) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Revenue Recognition [Abstract]
Payments for medicare cap liability		$ 3,439,000
Increase (decrease) in Medicare cap liability	$ 2,500,000	$ 1,800,000

XML

Revenue Recognition (Schedule Of Medicare Cap Liability Activity) (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Revenue Recognition [Abstract]
Beginning Balance January 1,	$ 8,260	$ 1,261
2014 measurement period	1,796
2013 measurement period		3,161
Payments	(3,439)
Ending Balance September 30,	$ 6,617	$ 4,422

XML

Segments

9 Months Ended

Sep. 30, 2014

Segments [Abstract]

Segments

3.   Segments

Service revenues and sales and after-tax earnings by business segment are as follows (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2014		2013		2014		2013
Service Revenues and Sales
VITAS	$	265,384	$	254,001	$	789,822	$	788,896
Roto-Rooter		93,005		86,885		287,049		275,829
Total	$	358,389	$	340,886	$	1,076,871	$	1,064,725
After-tax Earnings
VITAS	$	21,593	$	14,608	$	60,645	$	55,237
Roto-Rooter		9,848		8,181		30,599		19,218
Total		31,441		22,789		91,244		74,455
Corporate		(6,856)		(5,357)		(21,722)		(20,137)
Net income	$	24,585	$	17,432	$	69,522	$	54,318

We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as “Corporate”. 

XML

Revenue Recognition (Schedule Of Cost Of Charity Care) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue Recognition [Abstract]
Charity care cost	$ 1,827	$ 1,909	$ 5,518	$ 5,793

XML

Other Income - Net (Schedule Of Other Income - Net) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Other Income - Net [Abstract]
Market value gains/(losses) on assets held in deferred compensation trust	$ 896	$ (189)	$ 2,708	$ 2,346
Loss on disposal of property and equipment	(167)	(101)	(493)	(180)
Interest income - net	(13)	192	(5)	1,165
Other - net	(11)	8	67	(19)
Total other income - net	$ 705	$ (90)	$ 2,277	$ 3,312

XML

Consolidated Balance Sheet (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$ 18,562	$ 84,418
Accounts receivable less allowances of $13,887 (2013 - $12,590)	132,340	91,770
Inventories	6,385	6,703
Current deferred income taxes	14,543	20,257
Prepaid income taxes	3,488	3,690
Prepaid expenses	13,420	17,818
Total current assets	188,738	224,656
Investments of deferred compensation plans	47,780	42,465
Properties and equipment, at cost, less accumulated depreciation of $187,983 (2013 - $180,550)	101,845	92,955
Identifiable intangible assets less accumulated amortization of $32,644 (2013 - $32,055)	56,158	56,556
Goodwill	466,844	466,871
Other assets	8,143	10,198
Total Assets	869,508	893,701
Current liabilities
Accounts payable	57,067	41,758
Current portion of long-term debt	20,425	183,564
Income taxes	4,608	111
Accrued insurance	39,927	41,859
Accrued compensation	50,412	48,323
Accrued legal	685	23,210
Other current liabilities	24,131	25,161
Total current liabilities	197,255	363,986
Deferred income taxes	27,853	27,301
Long-term debt	153,125
Deferred compensation liabilities	47,736	42,348
Other liabilities	11,108	11,176
Total Liabilities	437,077	444,811
Commitments and contingencies
STOCKHOLDERS' EQUITY
Capital stock - authorized 80,000,000 shares $1 par; issued 33,199,078 shares (2013 - 32,245,226 shares)	33,199	32,245
Paid-in capital	528,973	481,011
Retained earnings	745,077	686,114
Treasury stock - 16,287,526 shares (2013 - 14,660,427)	(877,067)	(752,634)
Deferred compensation payable in Company stock	2,249	2,154
Total Stockholders' Equity	432,431	448,890
Total Liabilities and Stockholders' Equity	$ 869,508	$ 893,701

XML

Legal And Regulatory Matters (Details) (U.S. v. VITAS [Member], USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
U.S. v. VITAS [Member]
Loss Contingencies [Line Items]
Number of Patients			117
Current and former employees			10
Net (costs) credit incurred	$ (450,000)	$ 591,000	$ (1,600,000)	$ (1,400,000)

XML

Basis Of Presentation

9 Months Ended

Sep. 30, 2014

Basis Of Presentation [Abstract]

Basis Of Presentation

1.  Basis of Presentation

As used herein, the terms "We," "Company" and "Chemed" refer to Chemed Corporation or Chemed Corporation and its consolidated subsidiaries. 

We have prepared the accompanying unaudited consolidated financial statements of Chemed in accordance with Rule 10-01 of SEC Regulation S-X.  Consequently, we have omitted certain disclosures required under generally accepted accounting principles in the United States (“GAAP”) for complete financial statements. The                December 31, 2013 balance sheet data were derived from audited financial statements but do not include all disclosures required by GAAP.  However, in our opinion, the financial statements presented herein contain all adjustments, consisting only of normal recurring adjustments, necessary to state fairly our financial position, results of operations and cash flows.  These financial statements are prepared on the same basis as and should be read in conjunction with the audited Consolidated Financial Statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2013. 

XML

Earnings Per Share (Schedule Of Computation Of Earnings Per Share) (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]
Earnings, Income	$ 24,585	$ 17,432	$ 69,522	$ 54,318
Diluted earnings, Income	$ 24,585	$ 17,432	$ 69,522	$ 54,318
Earnings per Share	$ 1.44	$ 0.96	$ 4.03	$ 2.95
Earnings per Share, Diluted	$ 1.39	$ 0.94	$ 3.87	$ 2.89
Net Income, Earnings, Shares	17,039,000	18,184,000	17,263,000	18,436,000
Dilutive stock options, Shares	416,000	235,000	402,000	287,000
Nonvested stock awards, Shares	151,000	103,000	147,000	101,000
Conversion of Notes and impact of warrants outstanding, Shares	21,000		156,000
Net Income, Diluted Earnings, Shares	17,627,000	18,522,000	17,968,000	18,824,000

XML

Segments (Tables)

9 Months Ended

Sep. 30, 2014

Segments [Abstract]

Service Revenues And Sales And After-Tax Earnings By Business Segment

	Three months ended September 30,				Nine months ended September 30,
	2014		2013		2014		2013
Service Revenues and Sales
VITAS	$	265,384	$	254,001	$	789,822	$	788,896
Roto-Rooter		93,005		86,885		287,049		275,829
Total	$	358,389	$	340,886	$	1,076,871	$	1,064,725
After-tax Earnings
VITAS	$	21,593	$	14,608	$	60,645	$	55,237
Roto-Rooter		9,848		8,181		30,599		19,218
Total		31,441		22,789		91,244		74,455
Corporate		(6,856)		(5,357)		(21,722)		(20,137)
Net income	$	24,585	$	17,432	$	69,522	$	54,318

XML

Long-Term Debt (Narrative) (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
Debt Instrument [Line Items]
Repayment of convertible notes	$ 187,000,000
Shares issued in conjunction with the conversion feature of the Notes	249,000
Stock received in written call transaction	266,000
Standby letters of credit issued	36,900,000
Unused lines of credit	238,300,000
2014 Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument term	5 years
Deferred financing costs	900,000
2014 Credit Agreement [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Basis spread on variable interest rate	1.13%
2014 Credit Agreement [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Face amount of debt	350,000,000
2014 Credit Agreement [Member] | Medium-term Notes [Member]
Debt Instrument [Line Items]
Face amount of debt	$ 100,000,000

XML

Long-Term Debt (Tables)

9 Months Ended

Sep. 30, 2014

Long-Term Debt [Abstract]

Debt Outstanding

Revolver	$	74,800,000
Term loan		98,750,000
Total		173,550,000
Current portion of term and revolving loan		(20,425,000)
Long-term debt	$	153,125,000

Schedule of Principal Payments of the Term Loan

2014	$	1,250,000
2015		6,250,000
2016		7,500,000
2017		8,750,000
2018		10,000,000
2019		65,000,000
	$	98,750,000

Financial Debt Covenants

Description	Requirement
Leverage Ratio (Consolidated Indebtedness/Consolidated  Adj. EBITDA)	<  3.50 to 1.00
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges)	>  1.50 to 1.00
Annual Operating Lease Commitment	<  $50.0 million

XML

Revenue Recognition

9 Months Ended

Sep. 30, 2014

Revenue Recognition [Abstract]

Revenue Recognition

2. Revenue Recognition

Both the VITAS segment and the Roto-Rooter segment recognize service revenues and sales when the earnings process has been completed.  Generally, this occurs when services are provided or products are delivered.  VITAS recognizes revenue at the estimated realizable amount due from third-party payers.  Medicare payments are subject to certain limitations, as described below.

We actively monitor each of our hospice programs, by provider number, as to their specific admission, discharge rate and median length of stay data in an attempt to determine whether they are likely to exceed the annual per-beneficiary Medicare cap (“Medicare cap”).  Should we determine that revenues for a program are likely to exceed the Medicare cap based on projected trends, we attempt to institute corrective action to influence the patient mix or to increase patient admissions.  However, should we project our corrective action will not prevent that program from exceeding its Medicare cap, we estimate the amount of revenue recognized during the period that will require repayment to the Federal government under the Medicare cap and record the amount as a reduction to patient revenue. 

During the third quarter of 2014, we recorded $2.5 million Medicare cap liability for two programs’ projected 2014 measurement period liability.

During the nine months ended September 30, 2014 we recorded a net Medicare cap liability of $1.8 million for two programs’ projected 2014 measurement period liability offset by the reversal of Medicare cap liability for amounts recorded in the fourth quarter of 2013 for projected 2014 measurement period liability. Also during the nine months ended September 30, 2014, we received notice from a third party intermediary for amounts accrued related to the 2013 measurement period. As a result we repaid $3.4 million.

Shown below is the Medicare cap liability activity for the fiscal periods ended (in thousands):

	September 30,
	2014		2013
Beginning balance January 1,	$	8,260	$	1,261
2014 measurement period		1,796		-
2013 measurement period		-		3,161
Payments		(3,439)		-
Ending balance September 30,	$	6,617	$	4,422

Vitas provides charity care, in certain circumstances, to patients without charge when management of the hospice program determines, at the time services are performed, that the patient does not have the financial wherewithal to make payment.  There is no revenue or associated accounts receivable in the accompanying consolidated financial statements related to charity care.  The cost of charity care is calculated by taking the ratio of charity care days to total days of care and multiplying by total cost of care.  The cost of charity care is as follows (in thousands):

Three months ended September 30,				Nine months ended September 30,
2014			2013	2014		2013
$	1,827	$	1,909	$	5,518	$	5,793

XML

Consolidated Balance Sheet (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Consolidated Balance Sheet [Abstract]
Accounts receivable, allowances	$ 13,887	$ 12,590
Properties and equipment, accumulated depreciation	187,983	180,550
Identifiable intangible assets, accumulated amortization	$ 32,644	$ 32,055
Capital stock - authorized	80,000,000	80,000,000
Capital stock - par value	$ 1	$ 1
Capital stock - issued	33,199,078	32,245,226
Treasury stock	16,287,526	14,660,427

XML

Cash Overdrafts And Cash Equivalents

9 Months Ended

Sep. 30, 2014

Cash Overdrafts And Cash Equivalents [Abstract]

Cash Overdrafts And Cash Equivalents

12.  Cash Overdrafts and Cash Equivalents

Included in accounts payable at September 30, 2014 is cash overdrafts payable of $23.0 million (December 31, 2013 - $806,000).

From time to time throughout the year, we invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds.  We had $68,000 in cash equivalents as of September 30, 2014.  There was $23.1 million in cash equivalents as of December 31, 2013.  The weighted average rate of return for our cash equivalents was 0.09% at September  30, 2014 and 0.08% at December 31, 2013.

XML

Document And Entity Information	9 Months Ended
	Sep. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2014
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2014
Entity Registrant Name	CHEMED CORP
Trading Symbol	CHE
Entity Central Index Key	0000019584
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	17,010,464

XML

Financial Instruments

9 Months Ended

Sep. 30, 2014

Financial Instruments [Abstract]

Financial Instruments

13.   Financial Instruments

FASB’s authoritative guidance on fair value measurements defines a hierarchy which prioritizes the inputs in fair value measurements.  Level 1 measurements are measurements using quoted prices in active markets for identical assets or liabilities.  Level 2 measurements use significant other observable inputs.  Level 3 measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions.  In recording the fair value of assets and liabilities, companies must use the most reliable measurement available. 

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of          

September 30, 2014 (in thousands):

				Fair Value Measure
		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Mutual fund investments of deferred
compensation plans held in trust	$	47,780	$	47,780	$	-	$	-
Long-term debt		173,550		-		173,550		-

All outstanding long-term debt is at a floating interest rate tied to LIBOR. Therefore, the carrying amount is a reasonable estimation of fair value.

The following shows the carrying value, fair value and the hierarchy for our financial instruments as of      December 31, 2013 (in thousands):

				Fair Value Measure
		Carrying Value		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Mutual fund investments of deferred
compensation plans held in trust	$	42,465	$	42,465	$	-	$	-
Long-term debt		183,564		193,032		-		-

For cash and cash equivalents, accounts receivable and accounts payable, the carrying amount is a reasonable estimate of fair value because of the liquidity and short-term nature of these instruments.

XML

Consolidated Statement Of Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Consolidated Statement Of Income [Abstract]
Service revenues and sales	$ 358,389	$ 340,886	$ 1,076,871	$ 1,064,725
Cost of services provided and goods sold (excluding depreciation)	256,445	243,184	771,271	762,850
Selling, general and administrative expenses	53,566	48,870	162,886	157,537
Depreciation	7,450	6,971	21,871	20,665
Amortization	717	1,190	2,461	3,498
Other operating expenses		11,461		26,221
Total costs and expenses	318,178	311,676	958,489	970,771
Income from operations	40,211	29,210	118,382	93,954
Interest expense	(980)	(3,500)	(7,224)	(11,291)
Other income - net	705	(90)	2,277	3,312
Income before income taxes	39,936	25,620	113,435	85,975
Income taxes	(15,351)	(8,188)	(43,913)	(31,657)
Net income	$ 24,585	$ 17,432	$ 69,522	$ 54,318
Earnings Per Share
Net income	$ 1.44	$ 0.96	$ 4.03	$ 2.95
Average number of shares outstanding	17,039	18,184	17,263	18,436
Diluted Earnings Per Share
Net income	$ 1.39	$ 0.94	$ 3.87	$ 2.89
Average number of shares outstanding	17,627	18,522	17,968	18,824
Cash Dividends Per Share	$ 0.22	$ 0.20	$ 0.62	$ 0.56

XML

Stock-Based Compensation Plans

9 Months Ended

Sep. 30, 2014

Stock-Based Compensation Plans [Abstract]

Stock-Based Compensation Plans

7.   Stock-Based Compensation Plans

On February 21, 2014, the Compensation/Incentive Committee of the Board of Directors (“CIC”) granted 10,340 Performance Stock Units (“PSUs”) contingent upon the achievement of certain total shareholders return (“TSR”) targets as compared to the TSR of a group of peer companies for the three-year period ending December 31, 2016, the date at which such awards may vest.  The cumulative compensation cost of the TSR-based PSU award to be recorded over the three year service period is $1.2 million.

On February 21, 2014, the CIC also granted 14,061 PSUs contingent upon the achievement of certain earnings per share (“EPS”) targets for the three-year period ending December 31, 2016.  At the end of each reporting period, the Company estimates the number of shares that it believes will ultimately be earned and records that expense over the service period of the award.  We currently estimate the cumulative compensation cost of the EPS-based PSUs to be recorded over the three year service period is $1.2 million.

XML

Other Income - Net

9 Months Ended

Sep. 30, 2014

Other Income - Net [Abstract]

Other Income - Net

6.   Other Income – Net

Other income -- net comprises the following (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2014		2013		2014		2013
Market value gains/(losses) on assets held in
deferred compensation trust	$	896	$	(189)	$	2,708	$	2,346
Loss on disposal of property and equipment		(167)		(101)		(493)		(180)
Interest income - net		(13)		192		(5)		1,165
Other - net		(11)		8		67		(19)
Total other income - net	$	705	$	(90)	$	2,277	$	3,312

XML

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2014

Earnings Per Share [Abstract]

Schedule Of Computation Of Earnings Per Share

			Net Income
For the Three Months Ended September 30,		Income		Shares	Earnings per Share
2014
	Earnings	$	24,585	17,039	$	1.44
	Dilutive stock options		-	416
	Nonvested stock awards		-	151
	Impact of warrants outstanding		-	21
	Diluted earnings	$	24,585	17,627	$	1.39
2013
	Earnings	$	17,432	18,184	$	0.96
	Dilutive stock options		-	235
	Nonvested stock awards		-	103
	Diluted earnings	$	17,432	18,522	$	0.94

			Net Income
For the Nine Months Ended September 30,		Income		Shares	Earnings per Share
2014
	Earnings	$	69,522	17,263	$	4.03
	Dilutive stock options		-	402
	Nonvested stock awards		-	147
	Conversion of Notes and impact of warrants outstanding		-	156
	Diluted earnings	$	69,522	17,968	$	3.87
2013
	Earnings	$	54,318	18,436	$	2.95
	Dilutive stock options		-	287
	Nonvested stock awards		-	101
	Diluted earnings	$	54,318	18,824	$	2.89

XML

Capital Stock Repurchase Plan Transactions

9 Months Ended

Sep. 30, 2014

Capital Stock Repurchase Plan Transactions [Abstract]

Capital Stock Repurchase Plan Transactions

14.  Capital Stock Repurchase Plan Transactions

We repurchased the following capital stock for the three and nine-months ended September 30, 2014 and 2013:  

	Three months ended September 30,				Nine months ended September 30,
	2014		2013		2014		2013
Shares repurchased		400,000		1,032,754		1,082,934		1,313,455
Weighted average price per share	$	101.53	$	68.91	$	91.51	$	68.23

In February 2014, the Board of Directors authorized an additional $100 million for stock repurchase under Chemed’s existing share repurchase program. We currently have $22.7  million of authorization remaining under this share repurchase plan.

XML

Legal And Regulatory Matters

9 Months Ended

Sep. 30, 2014

Legal And Regulatory Matters [Abstract]

Legal And Regulatory Matters

10.  Legal and Regulatory Matters

The VITAS segment of the Company’s business operates in a heavily-regulated industry.  As a result, the Company is subjected to inquiries and investigations by various government agencies, as well as to lawsuits, including qui tam actions.  The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware.  It is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or estimable.

Regulatory Matters and Litigation

On January 12, 2012, a putative class action lawsuit was filed in the U.S. District Court for the Southern District of Ohio against the Company, David Williams, and Timothy O’Toole,  In re Chemed Corp. Securities Litigation, Civil Action No. 1:12-cv-28 (S.D. Ohio).  As the Company has previously disclosed, on February 6, 2014, the Plaintiffs, on behalf of a putative class of purchasers of Chemed Capital Stock between February 15, 2010 and May 2, 2013, inclusive, executed a stipulation of settlement with Defendants.  That settlement received final court approval on July 15, 2014, resulting in the dismissal of the case.  No appeal of that judgment has since been filed.  Defendants agreed to enter into this settlement in order to eliminate the burden, expense and distraction of further litigation.

In June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Western District of Texas,  United States, et al. ex rel. Urick v. VITAS HME Solutions, Inc. et al., 5:08-cv-0663 (“Urick”).  The U.S. Attorney filed a notice in May 2012 stating that it had decided not to intervene in the case at that time but indicating that it continues to investigate the allegations.  In June 2012, the complaint was unsealed.  The complaint asserts violations of the federal False Claims Act and the Texas Medicaid Fraud Prevention Act based on allegations of a conspiracy to submit to Medicare and Medicaid false claims involving hospice services for ineligible patients, unnecessary medical supplies, failing to satisfy certain prerequisites for payment, and altering patient records, including backdating patient revocations.  The suit was brought by Barbara Urick, a registered nurse in VITAS’s San Antonio program, against VITAS, certain of its affiliates, and several former VITAS employees, including physicians Justo Cisneros and Antonio Cavasos and nurses Sally Schwenk, Diane Anest, and Edith Reed.  In September 2012 and July 2013, the plaintiff dismissed all claims against the individual defendants.  The complaint was served on the VITAS entities on April 12, 2013.

Also in June 2011, the U.S. Attorney provided the Company with a partially unsealed qui tam complaint filed under seal in the U.S. District Court for the Northern District of Illinois, United States, et al. ex rel. Spottiswood v. Chemed Corp., 1:07-cv-4566 (“Spottiswood”).  In April 2012, the complaint was unsealed.  The U.S. Attorney and Attorney General for the State of Illinois filed notices in April and May 2012, respectively, stating that they had decided not to intervene in the case at that time but indicating that they continue to investigate the allegations.  Plaintiff filed an amended complaint in November 2012.  The complaint asserts violations of the federal False Claims Act and the Illinois Whistleblower Reward and Protection Act based on allegations that VITAS fraudulently billed Medicare and Medicaid for providing unwarranted continuous care services.  The suit was brought by Laura Spottiswood, a former part-time pool registered nurse at VITAS, against Chemed, VITAS, and a VITAS affiliate.  The complaint was served on the defendants on April 12, 2013.  On May 29 and June 4, 2013, respectively, the Court granted the government’s motion to partially intervene in Spottiswood and in Urick on the allegations that VITAS submitted or caused to be submitted false or fraudulent claims for continuous care and routine home care on behalf of certain ineligible Medicare beneficiaries.  The Court also transferred them to the U.S. District Court for the Western District of Missouri under docket Nos. 4:13-cv-505 and 4:13-cv-563, respectively.

On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries in the U.S. District Court for the Western District of Missouri, United States v. VITAS Hospice Services, LLC, et al., No. 4:13-cv-00449-BCW (the “2013 Action”).  Prior to that date, the Company received various subpoenas from the U.S. Department of Justice and OIG that have been previously disclosed.  The 2013 Action alleges that, since at least 2002, VITAS, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for continuous home care services when the patients were not eligible, the services were not provided, or the medical care was inappropriate, and (b) billing Medicare for patients who were not eligible for the Medicare hospice benefit because they did not have a life expectancy of six months or less if their illnesses ran their normal course.  This complaint seeks treble damages, statutory penalties, and the costs of the action, plus interest.  On August 1, 2013, the government filed its First Amended Complaint in the 2013 Action.  The First Amended Complaint changed and supplemented some of the allegations, but did not otherwise expand the causes of action or the nature of the relief sought against VITAS.  The defendants filed a motion to dismiss on September 24, 2013.  The Court denied the motion, except to the extent that claims were filed before July 24, 2002, on September 30, 2014.

On May 6, 2013, the U.S. District Court for the Western District of Missouri, at the request of the government, unsealed a qui tam complaint against VITAS and VITAS Healthcare Corporation of California,United States ex rel. Charles Gonzales v. VITAS Healthcare Corporation, et al., CV 12-0761-R (“Gonzales”).  The case was transferred from the Central District of California to the Western District of Missouri under docket No. 4:13-cv-344.  The government partially intervened in Gonzales.  The Gonzales complaint alleges that VITAS’ Los Angeles program falsely certified and recertified patients as eligible for the Medicare Hospice Benefit.  It alleges violations of the False Claims Act and seeks treble damages, civil penalties, recovery of costs, attorneys’ fees and expenses, and pre- and post-judgment interest.  

On September 25, 2013, the Court granted a joint motion by the government, the relators, and VITAS to consolidate the Spottiswood,  Urick, and  Gonzales complaints with the 2013 Action.  As a result, the First Amended Complaint will govern the consolidated federal claims brought by the United States and the relators for all purposes.  The relators and VITAS have stipulated that certain non-intervened claims will not be pursued by the relators.  The Spottiswood relator filed an action under the Illinois False Claims Act, The State of Illinois ex rel. Laura Spottiswood v. Chemed Corporation, et al., No. 14 L 2786 in the Circuit Court of Cook County, Illinois on March 6, 2014.  The Court granted the parties’ joint motion to place this case on its stay calendar, pending resolution of the 2013 Action.

VITAS has also received document subpoenas in related state matters.  In February 2010, VITAS received a civil investigative demand (“CID”) from the Texas Attorney General seeking documents from January 1, 2002 through the date of the CID, and interrogatory responses in connection with an investigation of possible fraudulent submission of Medicaid claims for non-qualifying patients and fraudulent shifting of costs from VITAS to the State of Texas and the United States.  The CID requested similar information sought by prior Department of Justice subpoenas, including policy and procedure manuals and information concerning Medicare and Medicaid billing, patient statistics and sales and marketing practices, together with information concerning record-keeping and retention practices, and medical records concerning 117 patients.  In September 2010, VITAS received a third CID from the Texas Attorney General seeking additional documents concerning business plans and results, revocation forms for certain patients, and electronic documents of 10 current and former employees.  In July 2012, VITAS received an investigative subpoena from the Florida Attorney General seeking documents previously produced in the course of prior government investigations as well as, for the period January 1, 2007 through the date of production, billing records and procedures; information concerning business results, plans, and strategies; documents concerning patient eligibility for hospice care; and certain information concerning employees and their compensation.

The net costs incurred related to U.S. v. Vitas and related regulatory matters were $450,000 and a $591,000 credit for the three months ended September 30, 2014 and 2013, respectively.  For the nine months ended September 30, 2014 and 2013, the net costs were $1.6 million and $1.4 million respectively.

In November 2013, two shareholder derivative lawsuits were filed against the Company’s current and former directors, as well as certain of its officers, both of which are covered by the Company’s commercial insurance.  On November 6, 2013, KBC Asset Management NV filed suit in the United States District Court for the District of Delaware, KBC Asset Management NV, derivatively on behalf of Chemed Corp. v. McNamara, et al., No. 13 Civ. 1854 (LPS) (D. Del.).  It sued Kevin McNamara, Joel Gemunder, Patrick Grace, Thomas Hutton, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, Arthur Tucker, Jr., George Walsh III, Frank Wood, Timothy O’Toole, David Williams and Ernest Mrozek, together with the Company as nominal defendant.  Plaintiff alleges that since at least 2004, Chemed, through VITAS, has submitted or caused the submission of false claims to Medicare.  The suit alleges a claim for breach of fiduciary duty against the individual defendants, and seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees. 

On November 14, 2013, Mildred A. North filed suit in the United States District Court for the Southern District of Ohio, North, derivatively on behalf of Chemed Corp. v. Kevin McNamara, el al., No. 13 Civ. 833 (MDB) (S.D. Ohio).  She sued Kevin McNamara, David Williams, Timothy O’Toole, Joel Gemunder, Patrick Grace, Walter Krebs, Andrea Lindell, Thomas Rice, Donald Saunders, George Walsh III, Frank Wood and Thomas Hutton, together with the Company as nominal defendant.  Plaintiff alleges that, between February 2010 and the present, the individual defendants breached their fiduciary duties as officers and directors of Chemed by, among other things, (a) allegedly causing VITAS to submit improper and ineligible claims to Medicare and Medicaid; and (b) allegedly misrepresenting the state of Chemed’s internal controls.  The suit alleges claims for breach of fiduciary duty, abuse of control and gross mismanagement against the individual defendants.  The complaint also alleges unjust enrichment and insider trading against Messrs. McNamara, Williams and O’Toole.  Plaintiff seeks (a) a declaration that the individual defendants breached their fiduciary duties to the Company; (b) an order requiring those defendants to pay compensatory damages, restitution and exemplary damages, in unspecified amounts, to the Company; (c) an order directing the Company to implement new policies and procedures; and (d) costs and disbursements incurred in bringing the action, including attorneys’ fees. 

On January 29, 2014 defendants in North filed a motion to transfer that case to Delaware under 28 U.S.C § 1404(a). On February 12, 2014, defendants in KBC filed a motion to dismiss that case pursuant to Federal Rules of Civil Procedure 23.1 and 12(b)(6).  On September 19, 2014, the Ohio court granted defendants’ motion to transfer North to Delaware.  Following that decision and in light of that transfer, on September 29, 2014, the Delaware court denied without prejudice defendants’ motion to dismiss KBC, and referred both cases to Magistrate Judge Burke.  Defendants intend to renew their motion to dismiss the claims and allegations in KBC once it has been determined how these two cases are to proceed.  On October 15, 2014, the plaintiff in KBC filed a motion seeking to consolidate KBC and North, to have plaintiff KBC appointed the sole lead plaintiff and its counsel, Motley Rice, sole lead counsel, and to designate KBC the sole operative complaint.  Plaintiff North has indicated that she does not oppose consolidation of the two cases, but otherwise opposes KBC’s motion with regard to the appointment of lead plaintiff and lead counsel and designation of the operative complaint.  On October 20, 2014, the Court stayed Defendants’ obligation to answer, move, or otherwise respond to the complaints in KBC and North pending further order of the Court.

The Company intends to defend vigorously against the allegations in each of the above lawsuits.  Regardless of the outcome of any of the preceding matters, responding to the subpoenas and dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, diversion of management time, and related publicity.  Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.

XML

Independent Contractor Operations

9 Months Ended

Sep. 30, 2014

Independent Contractor Operations [Abstract]

Independent Contractor Operations

8.   Independent Contractor Operations

The Roto-Rooter segment sublicenses with 68 independent contractors to operate certain plumbing repair and drain cleaning businesses in lesser-populated areas of the United States and Canada.  We had notes receivable from our independent contractors as of September 30, 2014 totaling $1.4 million (December 31, 2013 - $1.5 million).  In most cases these loans are fully or partially secured by equipment owned by the contractor.  The interest rates on the loans range from 0% to 8% per annum and the remaining terms of the loans range from 2 months to 5 years at September30, 2014.  We recorded the following from our independent contractors (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2014		2013		2014		2013
Revenues	$	8,751	$	8,054	$	26,964	$	24,418
Pretax profits		4,946		4,243		15,341		13,015

XML

Retirement Plans

9 Months Ended

Sep. 30, 2014

Retirement Plans [Abstract]

Retirement Plans

9.  Retirement Plans

All of the Company’s plans that provide retirement and similar benefits are defined contribution plans.  These expenses include the impact of market gains and losses on assets held in deferred compensation plans.  Expenses for the Company’s pension and profit-sharing plans, excess benefit plans and other similar plans are as follows (in thousands):

Three months ended September 30,				Nine months ended September 30,
2014		2013		2014		2013
$	3,635	$	2,098	$	10,856	$	9,796

XML

Concentration Of Risk

9 Months Ended

Sep. 30, 2014

Concentration Of Risk [Abstract]

Concentration Of Risk

11.  Concentration of Risk

VITAS has pharmacy services agreements ("Agreements") with Omnicare, Inc. and its subsidiaries (“OCR”) whereby OCR provides specified pharmacy services for VITAS and its hospice patients in geographical areas served by both VITAS and OCR.  The Agreements renew automatically for three-year terms.  Either party may cancel the Agreements at the end of any term by giving 30 days prior written notice.  VITAS made purchases from OCR of $8.8 million and $9.7 million for the three months ended September 30, 2014 and 2013, respectively.  VITAS made purchases from OCR of $26.5 million and $29.3 million for the nine months ended September 30, 2014 and 2013, respectively. For the three and nine month periods ending September 30, 2014 and 2013, respectively, purchases from this vendor represent approximately90% of all pharmacy services used by VITAS.

XML

Earnings Per Share (Narrative) (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]
Stock options excluded from computation of earnings per share	0		434,000	0	31,000
Shares issued in conjunction with the conversion feature of the Notes				249,000
Percent Of Senior Convertible Notes	1.875%			1.875%
Conversion of Notes and impact of warrants outstanding, Shares	21,000			156,000
Number of shares called by warrants	2,477,000			2,477,000
Warrants settled and recorded as an adjustment to paid in capital		$ 2.6

XML

Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2014

Revenue Recognition [Abstract]

Schedule Of Medicare Cap Liability Activity

	September 30,
	2014		2013
Beginning balance January 1,	$	8,260	$	1,261
2014 measurement period		1,796		-
2013 measurement period		-		3,161
Payments		(3,439)		-
Ending balance September 30,	$	6,617	$	4,422

Schedule Of Cost Of Charity Care

Three months ended September 30,				Nine months ended September 30,
2014			2013	2014		2013
$	1,827	$	1,909	$	5,518	$	5,793

XML

Independent Contractor Operations (Tables)

9 Months Ended

Sep. 30, 2014

Independent Contractor Operations [Abstract]

Schedule Of Independent Contractors

	Three months ended September 30,				Nine months ended September 30,
	2014		2013		2014		2013
Revenues	$	8,751	$	8,054	$	26,964	$	24,418
Pretax profits		4,946		4,243		15,341		13,015

XML

Capital Stock Repurchase Plan Transactions (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Feb. 28, 2013
Capital Stock Repurchase Plan Transactions [Abstract]
Stock repurchase program, amount authorized					$ 100
Shares repurchased	400,000	1,032,754	1,082,934	1,313,455
Weighted average price per share	$ 101.53	$ 68.91	$ 91.51	$ 68.23

XML

Stock-Based Compensation Plans (Narrative) (Details) (USD $) In Millions, except Share data, unless otherwise specified	0 Months Ended	9 Months Ended
	Feb. 21, 2014	Sep. 30, 2014
Performance Based TSR [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted	10,340
Shares vesting period, years		3 years
Cumulative compensation expense	$ 1.2
Performance Based EPS [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted	14,061
Shares vesting period, years		3 years
Cumulative compensation expense	$ 1.2

XML

Consolidated Statement Of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash Flows from Operating Activities
Net income	$ 69,522	$ 54,318
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	24,332	24,163
Deferred income taxes	5,630	(11,681)
Provision for uncollectible accounts receivable	9,573	8,211
Amortization of discount on convertible notes	3,392	6,450
Stock option expense	3,430	4,732
Amortization of debt issuance costs	697	1,421
Noncash portion of long-term incentive compensation	1,988	1,161
Changes in operating assets and liabilities, excluding amounts acquired in business combinations:
Decrease/(increase) in accounts receivable	(50,027)	5,293
Decrease in inventories	318	329
Decrease/(increase) in prepaid expenses	4,398	(6,183)
Increase/(decrease) in accounts payable and other current liabilities	(29,680)	48,967
Increase in income taxes	8,186	1,923
Increase in other assets	(3,138)	(5,002)
Increase in other liabilities	5,370	3,978
Excess tax benefit on share-based compensation	(3,737)	(2,507)
Other sources	755	285
Net cash provided by operating activities	51,009	135,858
Cash Flows from Investing Activities
Capital expenditures	(31,745)	(18,887)
Business combinations, net of cash acquired	(250)	(2,210)
Other sources	189	139
Net cash used by investing activities	(31,806)	(20,958)
Cash Flows from Financing Activities
Proceeds from revolving line of credit	308,600
Payments on revolving line of credit	(233,800)
Payments on other long-term debt	(188,206)
Proceeds from other long-term debt	100,000
Purchases of treasury stock	(99,103)	(89,611)
Dividends paid	(10,558)	(10,459)
Capital stock surrendered to pay taxes on stock-based compensation	(6,121)	(4,280)
Retirement of warrants	(2,645)
Proceeds from exercise of stock options	22,123	13,125
Excess tax benefit on share-based compensation	3,737	2,507
Increase/(decrease) in cash overdrafts payable	22,233	(10,928)
Debt issuance costs	(939)	(1,108)
Other uses	(380)	(473)
Net cash used by financing activities	(85,059)	(101,227)
Increase/(Decrease) in Cash and Cash Equivalents	(65,856)	13,673
Cash and cash equivalents at beginning of year	84,418	69,531
Cash and cash equivalents at end of period	$ 18,562	$ 83,204

XML

Long-Term Debt

9 Months Ended

Sep. 30, 2014

Long-Term Debt [Abstract]

Long-Term Debt

5.   Long-Term Debt

On May 15, 2014, we retired our Senior Convertible Notes (the “Notes”) outstanding.  We paid the $187.0 million of principal outstanding using a combination of cash on-hand and our existing revolving credit facility.  In addition, we issued 249,000 Chemed shares in conjunction with the conversion feature of the Notes.  At the time we issued the Notes, we also entered into a purchased call transaction to offset any potential economic dilution resulting from the conversion feature in the Notes.  As a result, we received 266,000 Chemed shares from the exercise of the purchased call transaction.  The issuance of shares under the conversion feature of the Notes, as well as the receipt of shares from the purchased call transaction were recorded as adjustments to paid-in capital during the quarter ended June 30, 2014.

On June 30, 2014, we replaced our existing credit agreement with the Third Amended and Restated Credit Agreement (“2014 Credit Agreement”).  Terms of the 2014 Credit Agreement consist of a five-year, $350 million revolving credit facility and a $100 million term loan.  The 2014 Credit Agreement has a floating interest rate that is currently LIBOR plus 113 basis points. 

The debt outstanding consists of the following:

Revolver	$	74,800,000
Term loan		98,750,000
Total		173,550,000
Current portion of term and revolving loan		(20,425,000)
Long-term debt	$	153,125,000

Scheduled principal payments of the term loan are as follows:

2014	$	1,250,000
2015		6,250,000
2016		7,500,000
2017		8,750,000
2018		10,000,000
2019		65,000,000
	$	98,750,000

Debt issuance costs associated with the existing credit agreement were not written-off as the lenders and their relative percentage participation in the facility did not change. With respect to the 2014 Credit Agreement, deferred financing costs were $0.9 million.  The 2014 Credit Agreement contains the following quarterly financial covenants:

Description	Requirement
Leverage Ratio (Consolidated Indebtedness/Consolidated  Adj. EBITDA)	<  3.50 to 1.00
Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges)	>  1.50 to 1.00
Annual Operating Lease Commitment	<  $50.0 million

We are in compliance with all debt covenants as of September 30, 2014. We have issued $36.9 million in standby letters of credit as of September 30, 2014 for insurance purposes.  Issued letters of credit reduce our available credit under the 2014 Credit Agreement.  As of September 30, 2014, we have approximately $238.3 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility.

XML

Retirement Plans (Tables)

9 Months Ended

Sep. 30, 2014

Retirement Plans [Abstract]

Schedule Of Expenses For Retirement, Profit-Sharing Plans, Excess Benefit Plans And Other Similar Plans

Three months ended September 30,				Nine months ended September 30,
2014		2013		2014		2013
$	3,635	$	2,098	$	10,856	$	9,796

XML

Long-Term Debt (Schedule of Principal Payments of the Term Loan) (Details) (USD $)	Sep. 30, 2014
Debt Instrument [Line Items]
Total	$ 173,550,000
Medium-term Notes [Member]
Debt Instrument [Line Items]
2014	1,250,000
2015	6,250,000
2016	7,500,000
2017	8,750,000
2018	10,000,000
2019	65,000,000
Total	$ 98,750,000

XML

Recent Accounting Statements

9 Months Ended

Sep. 30, 2014

Recent Accounting Statements [Abstract]

Recent Accounting Statements

15.  Recent Accounting Statements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update “ASU No. 2014-09 – Revenue from Contracts with Customers” which provides additional guidance to clarify the principles for recognizing revenue.  The standard will also be used to develop a common revenue standard for removing inconsistencies and weaknesses, improve comparability, provide more useful information to users through improved disclosure requirements, and simplify the preparation of financial statements.  The guidance is effective for fiscal years beginning after December 15, 2016.  We are currently evaluating the impact of this ASU on our existing revenue recognition policies and disclosures.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “ASU No. 2014-15 - Presentation of Financial Statements-Going Concern”.   ASU 2014-15 is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. This guidance is effective for us for the annual period ending December 31, 2016 and interim periods thereafter. We do not expect the adoption of this standard to have a material impact on our consolidated financial position, results of operations and cash flows.